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Summary 
Cardiovascular diseases (CVD) remains to be the leading cause of morbidity and mortality worldwide. 
Replacement of affected vascular tissues has been widely used to treat CVD such as coronary heart 
disease, aortic aneurysm and peripheral vascular disease. However, successful treatment of CVD is 
often limited by the lack of suitable autologous replacement tissue. Therefore, tissue engineering (TE) 
represents a promising solution to replace diseased vessels. TE aims at the development of constructs 
that integrate with the patient’s native tissue to restore physiologic function. The success of any TE 
approach is dependent on three main factors: (i) the cell source, (ii) the scaffold matrix, and (iii) the 
ambient biochemical and physical factors. During the last years several different starter materials and 
cell sources have been investigated. 
On the one hand, biodegradable scaffold matrixes form the basis of any in vitro tissue engineering 
approach by acting as a temporary matrix for cell proliferation and extracellular matrix deposition until 
the scaffold is replaced by neo-tissue. The present study systematically compares three frequently 
used polymers for the in vitro engineering of extracellular matrix based on poly-glycolic acid (PGA) 
under static as well as dynamic conditions. Ultra-structural analysis was used to examine the polymer 
structure. For tissue engineering (TE) three human fibroblast cell lines were seeded on either PGA-
poly-4-hydroxybutyrate (P4HB), PGA-poly-lactic acid (PLA) or PGA-poly–caprolactone (PCL) patches. 
Later, these patches were analyzed qualitatively and quantitatively. We found that PGA-P4HB and 
PGA-PLA scaffolds enhance tissue formation significantly higher than PGA-PCL scaffolds. Polymer 
remnants were visualized by polarization microscopy. In addition, biomechanical properties of the 
tissue engineered patches were determined in comparison to native tissue. This study may allow 
future studies to specifically select certain polymer starter matrices aiming at specific tissue properties 
of the bioengineered constructs in vitro. 
On the other hand, an ideal cell source for human therapeutic and disease modeling applications 
should be easily accessible and possess unlimited differentiation and expansion potential. Human 
induced pluripotent stem cells (hiPSCs) derived from peripheral blood mononuclear cells (PBMCs) 
represent a promising source given their ease of harvest combined with their pluripotent nature.  
Therefore, hiPSCs were generated based on PBMCs and differentiated into smooth muscle cells (SMCs) 
as well as endothelial cells (ECs). These cells were seeded onto PGA-P4HB starter matrices and cultured 
under static or dynamic conditions to induce tissue formation in vitro. Resulting tissue-engineered 
vascular grafts (TEVGs) showed abundant amounts of extracellular matrix, containing an αSMA-
positive layer in the interstitium and a thin luminal layer of vWF-positive cells approximating native 
vessels. These results pave the way for developing autologous PBMC-derived hiPSC-based vascular 
constructs for therapeutic applications or disease modelling. 
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Zusammenfassung 
Herzkreislauferkrankungen zählen zu den häufigsten Krankheiten und sind die Todesursache Nummer 1 
weltweit. In vielen Fällen ist eine Bypass-Operation unumgänglich, wie zum Beispiel bei koronare 
Herzerkrankungen, Aortenaneurysma oder peripheren Gefässkrankheiten. Da oftmals die körpereigenen 
Blutgefässe des Patienten ungeeignet sind, ist diese Behandlung nicht immer möglich. Tissue engineering 
(TE) stellt daher eine vielversprechende Lösung dar. Ziel des TEs ist es ein künstlich erzeugtes 
Ersatzkonstrukt zu produzieren, welches im Patienten die physiologische Funktion ersetzt. 
Der Erfolg vom TE hängt von 3 Hauptfaktoren ab: (i) der Zellquelle, (ii) dem Zellträger (= Scaffold) und (iii) 
den biochemischen und physikalischen Umgebungsfaktoren. Während der letzten Jahre wurde viele 
verschiedene Materialien und Zelltypen getestet. 
Das abbaubare Scaffold fungiert als Gerüst für den Zellwachstum und der Gewebeneubildung. Die 
vorliegende Studie vergleicht systematisch 3 häufig verwendete Polymere in Kombination mit einer 
Polyglykolsäure (PGA) unter statischen und dynamischen Bedingungen. Zur Visualisierung der 
Polymerstruktur wurde eine Ultrastrukturanalyse durchgeführt. Für die Gewebezüchtung wurden 3 
verschiedene Fibroblastenzelllinien auf entweder PGA-Polyhydroxybuttersäure (P4HB), PGA-
Polymilchsäuren (PLA) oder PGA-Polycaprolacton (PCL) kultiviert. Anschliessend wurden die 
Gewebekonstrukte, sogenannte Patches, qualitativ und quantitativ analysiert. PGA-P4HB und PGA-PLA 
stimulierte signifikant mehr die Gewebeneubildung als PGA-PCL. Polymer-Relikte wurden mittels 
Polarisationsmikroskopie dargestellt. Die biomechanischen Eigenschaften der gezüchteten Patches wurden 
im Vergleich zu nativen Gewebe gemessen. Diese Studie hilft eine ideale Auswahl eines geeigneten 
Scaffolds mit spezifischen Eigenschaften zu treffen. 
Eine ideale Zellquelle für humane therapeutische Anwendungen und der Entwicklung eines 
Krankheitsmodels, sollte leicht zu gewinnen sein, und zudem unbegrenztes Differenzierungs- und 
Wachstumspotenzial aufweisen. Humane induzierte pluripotente Stammzellen (iPSCs) gewonnen aus 
peripheren mononukleären Blutzellen (PBMCs) stellen aufgrund der leichten Verfügbarkeit und dem 
pluripotentem Charakter eine vielversprechende Ressource dar. Aus diesem Grund haben wir PBMCs in 
iPSCs reprogrammiert und anschliessend in glatte Muskelzellen beziehungsweise in Endothelzellen 
differenziert. Beide Zelltypen wurden auf einem PGA-P4HB Scaffold statisch oder dynamisch kultiviert, um 
die Gewebeneubildung zu stimulieren. Die entstandenen autologen Gefässprothesen wiesen eine 
neugebildete extrazelluläre Matrix auf. Das Interstitium besteht aus glatten Muskelzellen, des Weiteren ist 
eine dünne Schicht von Endothelzellen im Lumen zu erkennen - vergleichbar mit nativen Blutgefässen. 
Diese Resultate ebenen den Weg für die Erzeugung eines Gefässkonstruktes für therapeutische 
Anwendungen und der Entwicklung eines Krankheitsmodels basierend auf iPSCs von körpereigenem Blut. 
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1.1 Introduction 
1.1.1 Cardiovascular diseases and current therapies 
Cardiovascular diseases (CVDs) are the leading cause of death and disability worldwide, claiming 17.3 million 
lives each year and accounting for 30% of all global deaths [1]. Due to an increase of co-morbidities an ever 
ageing population, mortality numbers are expected to increase to about 23.3 million a year in 2030 [1]. CVDs 
in general cost more than any other disease and are projected to remain the single leading cause of death. 
The enormous annually costs related to this type of diseases has reached more than $33 billion in the US and 
more than £700 million in the UK [1]. Moreover, the total direct (health expenditures) and indirect 
(decreased productivity resulting from morbidity and mortality) costs of cardiovascular disease and stroke in 
the United States for 2010 is estimated at 503.2 billion dollars, from which the total hospital costs projected 
for the year 2010 are estimated to be 155.7 billion dollars [2].  
Unfortunately, in many situations the successful treatment of vascular diseases is limited by the lack of 
suitable autologous tissue to serve as vascular conduits to replace or bypass diseased or occluded vessels or 
repair or replace dysfunctional valves. Originally, autologous vascular grafts have been used in the field of 
reconstructive arterial surgery to treat vascular diseases, such as atherosclerosis that lead to the sequel of 
myocardial infarction and stroke [3]. However, their preparation increases time, cost, and the potential for 
morbidity to the surgical procedure [4, 5]. Therefore bypass grafts engineered from synthetic materials, e.g. 
Dacron or ePTFE, have been developed and successfully used for the replacement of larger vessels, i.e. 6–10 
mm in diameter [6, 7]. However, when used in the coronary system (inner diameter <6 mm) occluding of the 
vessels is a major problem due to thrombosis and hyperplasia.  
Valvular heart disease is another important cause of morbidity and mortality and the number of patients 
requiring heart valve replacement is approximately 280.000 annually worldwide [8]. As the group of 
congenital heart disease patients is expected to increase and the number of valve replacements is estimated 
to triple to over 850.000 over the upcoming five decades [9], the search for alternative heart valve 
replacements is ongoing. Cost wise, the development of a living valve replacement, i.e. by tissue engineering 
technologies, could save up to 36 billion dollars per 10 years for just US healthcare by eliminating both re-
operations, to replace degenerated cryopreserved homografts, and the total cost per patient lifetime after 
mechanical valve implantation [10]. In addition, for infants and children, the elimination of re-operations to 
replace non-growing valve replacements will reduce their mortality rate and suffering. However, currently 
available valve substitutes are either mechanical or bioprosthetic valves. Despite excellent durability, 
mechanical valves have a substantial risk of thromboembolic complications. Additionally, the required life-
long anticoagulation therapy potentiates hemorrhagic complications. In contrast, bioprosthetic valves show 
similar flow patterns to that of the native heart valves and, therefore, have a low risk of thromboembolism 
without anticoagulation. However, their durability is limited due to calcific or noncalcific tissue deterioration 
[11].  
  Introduction 
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A major drawback of all artificial cardiovascular replacements is their absence of repair, remodeling and 
growth capacity, the latter being particularly important in children and young adults. Tissue engineering is 
suggested as a solution to these problems by replacing tissue or organ function with engineered tissue 
created with the help of bioresorbable starter materials. The ultimate goal in cardiovascular tissue 
engineering is to develop autologous tissue engineered vascular grafts (TEVGs) and – heart valves (TEHVs) 
that are immunologically compatible, non-thrombogenic, and possess growth and remodeling capacity. The 
success of an engineered tissue replacement is based on mimicking the composition and structure of the 
original tissue. Therefore it is necessary to understand the specific demands of the cardiovascular system 
requiring an enormous strength, flexibility and durability of the engineered structures, as well as a high 
degree of adaptive capacity to cope with changes due to growth, physical activity and pathological 
conditions. 
1.1.2 Principles of tissue engineering 
The field of tissue-engineering applies the principles of biology and engineering to the development of 
biological substitutes for the repair or regeneration of tissue or organ function [12]. In 1993, Langer and 
Vacanti summarized the early developments in this field and defined the original tissue engineering paradigm 
that comprises a scaffold which is seeded with cells isolated from the recipient, subsequent in-vitro tissue 
formation and in-vivo tissue growth and remodeling following implantation [13]. The in-vivo phase can 
involve recruitment of the recipient’s inflammatory cells, resulting in a combination of seeded and recipient-
derived new cells in the engineered construct [14]. Both in-vitro and in-vivo, the key processes during tissue 
formation and maturation are cell proliferation and migration, extracellular matrix production and 
organization, and scaffold degradation. These capacities of the tissue engineered construct that enable repair 
of structural injury, remodeling of the extracellular matrix, and potential growth are crucial for long-term 
success of the living engineered tissues [15]. Various approaches to engineer such durable tissue constructs 
have been investigated and can be roughly divided into three groups, namely in-vitro, in-vivo, or in-situ tissue 
engineering.  
In-vitro tissue engineering: The first approach aims at the development of the construct in-vitro according 
to the classical paradigm. After seeding (autologous) cells onto different types of scaffold material, the 
construct is cultured in-vitro to stimulate tissue formation.  
In-vivo tissue engineering: Secondly, the in-vivo tissue engineering approach relies on autologous tissue 
formation by intraperitoneal implantation of a scaffold [16-20]. After sufficient autologous tissue formation 
in-vivo, the construct is transplanted to serve as a cardiovascular replacement. Although this is a very 
attractive method to create autologous tissue, the current status for this approach is that the volume fraction 
of cellular phenotypes is unbalanced, resulting in for example inadequate remodeling of heart valve 
replacements [16]. 
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In-situ tissue engineering: The third approach, although not fully complying with the classical concept of 
tissue-engineering as defined by Langer and Vacanti, made the first step towards clinical implementation by 
implanting a scaffold into the patient relying on spontaneous endogenous cellular repopulation [21]. For this 
in-situ tissue-engineering approach the regenerative capacity of the body is utilized. Suitable starter 
materials are implanted directly, without or directly after in-vitro preseeding, in order to recruit endogenous 
cells in-vivo. More recently, direct implantation of smart synthetic scaffold materials is proposed that actively 
attract the circulating endogenous cells. It is hypothesized that the scaffold will be populated by endogenous 
cells and subsequently, in-vivo tissue formation will take over the function of the degrading scaffold [22].  
As will be reviewed in this chapter, various scaffold materials are extensively investigated for the in-vitro and 
the in-situ approaches of cardiovascular tissue engineering. These synthetic or natural based materials are 
used to create heart valves and vessels (see also Table 1 and 2) and to a lesser extend to create cardiac muscle 
tissue. Additionally, various cell sources are investigated for tissue engineering.  
1.1.3 Cell sources for cardiovascular tissue engineering  
Despite being most important for the viable part of the construct, in contrast to the controllable properties 
of the starter materials, the cell source is still the least controllable factor. Their regenerative capacity and 
quality to form tissue relies on the characteristics of the origin and thus varies between individual donors 
and original organ tissue. A variety of cell types have been investigated for cardiovascular tissue engineering. 
For human applications, the ideal cells should be non-immunogenic, functional, and easy to isolate and 
expand [23]. Obviously, the cell sources mostly investigated for cardiovascular tissue engineering are the 
non-immunogenic autologous endothelial cells (ECs), smooth muscle cells (SMCs), and (myo) fibroblasts, as 
listed in Table 1 and 2. In order to obtain autologous cells, a piece of donor tissue is dissociated into individual 
cells, expanded in culture and finally attached to a scaffold and implanted. 
During the last years stem cells have attracted more attention and have become an important cell source for 
tissue engineering to replace lost host cells or to induce endogenous repopulation, in particular for cardiac 
muscle regeneration [24, 25]. Stem cells can be found in embryos, fetuses, and in adults and by definition 
they have the ability to reproduce themselves for a long period of time (self-renewal) and to give rise to 
different cells types (differentiation). There exist different stem cells, depending on their differentiation 
potential: the embryonic stem cells (ESCs) and the adult stem cells. The ESCs have the ability to give rise to 
all types of cells that form the three germ layers (mesoderm, endoderm, and ectoderm) from which all the 
cells of the body arise. ESCs are derived from the pre-implantation embryo, precisely from a group of 
pluripotent cells called inner cell mass (ICM). Once removed from the blastocyst, the cells of the ICM can be 
cultured under special conditions in-vitro and are then called ESCs [26, 27]. Just few studies have described 
attempts to engineer ESCs derived patches for cardiac repair [28-30]. For example, Ke et al. implanted 
scaffolds seeded with undifferentiated mouse ESCs in mice whereby scar size and ventricular dilatation were 
reduced [28]. Despite initial success [30], ethical issues, immunogenic and tumorigenic problems are the 
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major drawbacks. The adult stem cells have a more restricted (multipotent) differentiation potential 
compared to ESCs. They are found in adult organisms where they can give rise to specialized cells that give 
rise to the different tissues of the body. Adult stem cells serve for both homeostasis in healthy tissues and 
for regeneration of defective tissues [31]. Most of the recent investigations were focusing on using bone 
marrow stromal cells (BMSCs) and adipose-derived stem cells (ASCs) for cardiovascular tissue engineering 
[32, 33]. 
Recently, another interesting cell source for regenerative medicine, the induced pluripotent stem cell (iPSC), 
has become available. As part of this approach differentiated, adult cells have been genetically 
reprogrammed to an embryonic stem–like state with pluripotent differentiation capabilities. In 2006 
Takahashi and Yamanaka demonstrated the induction of pluripotent stem cells from mouse embryonic and 
adult fibroblasts [34]. Using genetic reprogramming with the transcription factors Oct4, Sox2, Klf4 and c-Myc, 
somatic cells converted into iPSCs. iPSCs are very similar in morphology, proliferation and gene expression 
to ESCs [35] and represent a powerful tool in regenerative medicine. Unfortunately, iPSCs have been 
associated the risk of teratoma formation and so more investigation is needed into the use of these cells for 
autologous cell based therapies such as cardiovascular tissue engineering. An open question is still whether 
an optimal approach would involve seeding with undifferentiated iPScs or rather using these cells to make a 
differentiated cell line of SMCs and/or ECs before seeding them onto scaffold matrices for cardiovascular 
tissue engineering [36]. 
1.2 Polymeric starter matrices for cardiovascular tissue engineering  
The use of polymeric materials to serve as starter matrices for cardiovascular tissue engineering has been 
extensively investigated. It is the cyclic loading of the cardiovascular system that requires significant 
durability and flexibility of the tissue-engineered cardiovascular replacements and consequently appropriate 
mechanical properties of the starting scaffolds to endure the cyclic stresses and strains exerted after 
implantation. The mechanical properties of the scaffold also provide an important stimulus to the cells for 
extracellular matrix (ECM) production and remodeling, as the cells experience different local stresses and 
strains depending on the biomechanical profile of the scaffold. However, these mechanical cues - as result 
of the scaffold stiffness - can modulate the differentiation of cells into pathological phenotypes, e.g. 
osteoblastic or myofibroblastic differentiation [37]. Additionally, bioactive factors can be incorporated into 
the scaffold that can direct local cellular function, or promote recruitment of specific cell types via 
chemotaxis.  
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Figure 1: Example of porous scaffolds for cardiovascular tissue engineering. (A) Photograph of an electrospun poly(ε-caprolactone) heart valve 
demonstrating 3D valve architecture. (B) Photograph of a PGA tube for culture of a vascular graft. (C) Scanning electron micrograph of the 
microstructure showing the random aligned microfibers.  Scale bars represent 1 cm in A and B and 100 µm in C. (Images courtesy of M. Simonet and 
R. Stenger.) 
1.2.1 Synthetic polymers 
Synthetic polymers have been extensively used in the field of tissue engineering, mainly due to their high 
durability and mechanical strength. Additionally, production conditions of synthetic polymers can be tightly 
controlled, thus, mechanical and physical properties are predictable and well defined. In addition, these 
scaffolds are less expensive, better reproducible and may be stored off-the-shelf over longer time periods. 
These characteristics make synthetic polymers to an interesting raw material for scaffold fabrication (see also 
Fig. 1). Nevertheless, their biocompatibility issues harbor also complications. In the following, the most 
important synthetic polymer materials for cardiovascular tissue engineering are presented in a summarized 
fashion. 
1.2.1.1 Non-degradable synthetic polymers 
Expanded polytetrafluoroethylene (ePTFE), polyethylene terephthalate (PET) and polyurethane (PU) have 
been used to produce synthetic vascular grafts [38]. ePTFE is a porous polymer with an electronegative 
luminal surface that is nondegradable. The chemical composition supports low thrombogenicity, lower rates 
of restenosis and hemostasis, and less calcification [39, 40]. e-PTFE grafts have been  used  as vein grafts, but 
only 45% of standard ePTFE grafts are patent as femoropopliteal bypass grafts at 5 years, however, 
autologous vein grafts have 60 to 80% patency [41, 42]. In contrast, PET is less used as a graft for 
femoropopliteal bypass surgery but is more common used for aortic replacement. PET, or also called 
Dacron®, is a thermoplastic polymer manufactured by Maquet Cardiovascular Inc.. Dacron displays a good 
stability and can exist for more than 10 years after implantation without significant deterioration [42]. 
However, ePTFE and PET surfaces are thrombogenic and relatively rigid, they are not suitable for the 
fabrication of small diameter vascular grafts [43]. PU has been suggested as a good alternative due to it is 
both haemocompatible and elastic [44]. In order to improve synthetic graft function and yield biohybrid 
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conduits, different components have been added to the graft design. For instance, Nakawaga et al. 
engineered a poly(ether-urethane) graft reinforced with knitted polyester fibers for hemodialysis that  was 
finally observed to be more durable than ePTFE [45]. Unfortunately, all three polymers have the disadvantage 
of being a synthetic non-degradable material and can cause a foreign body reaction with increased chances 
of thrombus formation. As the ideal scaffold for tissue engineering should demonstrate bioresorbable 
properties, the synthetic bioresorbable polymers have found extensive applications in tissue engineering. 
1.2.1.2 Bioresorbable synthetic polymers  
Bioresorbable synthetic polymers including poly(glycolic acid) (PGA), poly(lactic acid) (PLA), poly(hydroxy 
alkanoate) (PHA), poly(caprolactone) (PCL) and their copolymers have generated immense interest as tissue 
engineering materials due to their degradable properties. The degradation of implants is of special interest 
for the medical industry, as no further surgical procedure is required to remove the implant. Biomaterials 
used in clinical applications should have degradation and resorption rates which are compatible with the 
healing rates of the neotissue, c.q. there must be a balance between material degradation and ECM 
production [46, 47]. Polymers can degrade by (1) hydrolysis, (2) oxidation ,(3) enzymatic, and (4) physical 
conditions [48]. Production conditions of synthetic polymers can be controlled, thus, mechanical and physical 
properties are predictable including degradation rates and elastic modulus. Furthermore, these scaffolds are 
less expensive, better reproducible and may be stored over longer time periods. These characteristics make 
synthetic polymers to an intensely interesting raw material for scaffold fabrication. 
Because the words biodegradable and bioresorbable are often used misleadingly in literature, we will 
distinguishing them according to the following definitions formulated by Vert et al. [49, 50]: The term 
biodegradable applies to polymeric materials and solid devices that undergo dispersion as consequence of 
macromolecular degradation. Although degradation products can be removed from the site of action, their 
degradation products will not completely be eliminated and remain inside the human body. Bioresorbable 
materials are solid polymers and devices that degrade into non-toxic products (low–molecular weight 
compounds) which will be eliminated via metabolic pathways (i.e. the citric acid cycle) or directly via renal 
excretion without residual side effects [49, 50]. As in tissue engineering one aims to develop substitutes with 
the capacity to become living copies of their native counterparts without leaving remnants of the starter 
materials in the body, this chapter focusses on the available bioresorbable starter materials used for 
cardiovascular tissue engineering.  
 
Aliphatic Polyesters have been known and studied since 1930s [51]. Their success in tissue engineering relies 
mainly on their degradability and biocompatibility, as well as their good processability and mechanical 
feature. Currently, the most widely investigated and most commonly used biomedical aliphatic polyesters 
are PGA, PLA, and PCL. PGA is a rigid thermoplastic material with high crystallinity, whereby it is not soluble 
in most organic solvents. PGA is usually synthesized by ring-opening polymerization of glycolide, the cyclic 
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dimer of glycolic acid [52]. Similarly, lactic acid is polymerized to synthesize PLA. Lactic acid, which is normally 
produced by muscular contraction, can be eliminated through the citric acid cycle whereas glycolic acid may 
be eliminated directly in urine or may be converted to enter citric acid via pyruvic acid [53]. Due to the chiral 
nature of PLA, several distinct forms of exist: poly-L-lactide (PLLA), poly-D-lactideD (PDLA) and LD racemic 
(PDLLA), respectively. It is known that the characteristic of PLA are highly affected by stereo-isomeric L/D 
ratio of lactate units. Generally, the increased stereo-isomeric ratio decreases the crystallinity, whereby the 
degradation is enhanced. For example, degradation of PLA is faster than for PDLA due to the lower 
crystallinity of PLA. 
PCL is a semi-crystalline aliphatic polyester which is synthesized by ring-opening polymerization of ε-
caprolactone [54, 55]. It displays good mechanical characteristics, such as high elongation and strength. PCL 
degrades very slowly in-vivo by enzymatic action and by hydrolysis [54]. All three polyesters are a Food and 
Drug Administration (FDA) approved polymers for clinical use [56]. 
In 1998, Shinoka et al. reported surgical implantation of TEVGs in lambs, in which scaffolds were constructed 
from autologous myofibroblasts and endothelial cells seeded onto PGA grafts [57]. This study demonstrated 
the first vascular graft using autologous cells that yielded a viable structure [57]. Despite PGA is a 
bioresorbable polymer, breakdown products are acidic, which could induce an inflammatory response. 
Furthermore, PGA degrades faster than PLA that result in a low mechanical property of TEVGs [58]. Further 
studies have been conducte , for instance, by using PGA-PLLA scaffolds for microvessels in mice [59] or 
scaffolds composed of polyglycolide knitted fiber, and an L-lactide and ε-caprolactone copolymer sponge for 
TEVGs in a canine inferior vena cava model [60]. The hybrid polymeric scaffold fabricated from either PGA or 
PLA fiber-based mesh coated with a 50:50 copolymer of L-lactide and ε-caprolactone (PCLA/PGA or 
PCLA/PLA) are more elastic than the PGA scaffold, resulting in an improved compliance match between the 
vessel and the conduit, resulting in better surgical handling characteristics [61].  
 
Polyhydroxyalcanoates (PHA): Another group of polyesters is the PHA family that is built from hydroxyacids 
produced by microorganisms under unbalanced growth conditions [62]. They are generally bioresorbable 
and thermoprocessable and includes poly-3-hydroxybutyrate (PHB), copolymers of 3-hydroxybutyrate and 
3-hydroxyvalerate (PHBV), poly-4-hydroxybutyrate (P4HB), copolymers of 3-hydroxybutyrate and 3-
hydroxyhexanoate (PHBHHx) and poly-3-hydroxyoctanoate (PHO) The PHA family polymers have been 
displayed to be convenient for tissue engineering [63]. However, a disadvantage of some PHA polymers is 
their limited availability and the time-consuming production by bacteria. In order to adjust mechanical 
features or biocompatibility PHA polymers can be either blended, surface modified or composed with other 
polymers, enzymes or inorganic materials [64]. Additionally, their degradation rate can be tailored by varying 
their copolymer ratio. For example in 1999, TEVGs based on a PGA and PHA scaffold were implanted in the 
abdominal aortas of lambs and successfully followed up to 5 months in-vivo. Overtime, the mechanical 
properties of these preseeded TEVGs changed towards those of native blood vessels [65]. For both heart 
  Introduction 
 23 
 
valve and vascular tissue engineering the use of PGA coated with P4HB, meaning the combination of the 
thermoplastic characteristic of P4HB and the high porosity of PGA, has been investigated intensively 
presenting promising results in in-vitro and pre-clinical studies [33, 66-70]. Hoerstrup et al. was in 2006 the 
first to provide the evidence of growth of living, functional pulmonary arteries engineered from vascular cells 
seeded on PGA/P4HB scaffolds in a growing lamb model [71]. The evidence of the growth and remodeling 
capacity of these implants proved their potential also for use in pediatric applications. 
1.2.2 Bioresorbable natural polymers  
Whereas synthetic materials have performed better in durability and strength, they pale in comparison with 
the functional capabilities of natural tissues. A good alternative to the synthetic polymers are natural 
polymers which possess biologically recognizable side groups. The category of natural-based materials for 
scaffolds includes polysaccharides (aliginate, chitin/chitosan, hyaluronic acid derivate), proteins (soy, 
collagen, fibrin, gels, and silk) or decellularized extracellular matrix (ECM). Natural polymers are used as pure 
materials or in combination with synthetic polymers or inorganic substances to produce scaffolds [72-74]. 
The natural polymers mostly used for cardiovascular tissue engineering are collagen, fibrin, and 
decellularized ECM. 
1.2.2.1 Polysaccharides 
Polysaccharides are polymeric carbohydrates consist of long chains of monosaccharide units, which are 
linked together by O-glycosidic bonds. Physical properties, such as solubility, gelation and surface properties 
can be influenced by monosaccharide composition, chain shapes and molecular weight. Polysaccharides 
show good hemocompatibility properties, due to chemical similarities with heparin. Furthermore, they are 
non-toxic, display interaction with living cells and, most of them have low costs in comparison with others 
biopolymers such as collagen [75]. Several polysaccharidic polymers, including chitosan, aliginate and starch 
have been widely proposed as scaffold materials in tissue engineering applications and will be described in 
more detail in the following sections. 
 
Chitosan is the N-deacetylated derivative of chitin, a natural polysaccharide that is present in the hard 
exoskeletons of crustaceans and insects [76]. Chitosan is a relatively inexpensive product because chitin is 
one of the most common polysaccharides found in nature. Recently chitosan has started to be interesting in 
the tissue-engineering field due to several desirable properties, for instance, (i) the body reaction is minimal, 
(ii) process conditions are mild, and (iii) properties are controllable [77, 78]. In addition, chitosan is more 
bioactive than other degradable polymer leading to acceleration of wound healing. It has already been used 
for the engineering of cartilage, nerve, and liver [78]. Low strength and inconsistent behavior with seeded 
cells are difficulties which are associated with chitosan [79]. Nevertheless, in order to increase its strength 
and cell-attachment ability it can be combined with other materials such as synthetic polymers [80]. A variety 
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of formats including hydrogels, microcapsules, membranous films, sponges, tubes, and a variety of three-
dimensional porous structure have been investigated by using chitin-based materials [81, 82]. Firstly, in 1999 
Matthew et al. fabricated a family of chitosan scaffolds, including heparin-modified porous tubes, which had 
promising potential for application in TEVG [83]. Nevertheless, researchers developed a chitosan-based 
tubular scaffold which displayed proper swelling property, burst strength of almost 4000 mmHg, and high 
suture-retention strength not until 2006 [84]. 
 
Alginate is a linear polysaccharide derived from brown algae and is composed of repeating guluronic and 
manuronic units. Physical and mechanical properties of alginate are highly related to chain length. Alginate 
is a bioresorbable polymers that forms a solid gel under mild processing conditions, thus cells can be 
entrapped into beads and other shapes [85, 86]. Furthermore, encapsulation of certain cell types into 
alginate beads may actually improve cell survival and growth [87]. Some disadvantages of alginate have been 
published, including mechanical weakness and poor cell adhesion [85]. Again, to overcome these limitations, 
the strength and cell behavior of alginate have been enhanced by combining alginate with agarose [87] and 
chitosan [85]. Nevertheless, alginate has been investigated in liver [88], heart [89], and cartilage [90] tissue-
engineering. For example, Leor et al. demonstrated the feasibility of bioengineering a cardiac tissue within 
alginate scaffolds [91]. They implanted a cardiac graft onto rat infarcted myocardium which stimulated 
intense neovascularization from neighboring coronaries [91]. 
 
Starch, a natural polymer, is a material that is also commonly used in tissue engineering. It is deposited in 
the chloroplasts of plant cells (e.g. corn, rice, and wheat) as insoluble granules composed of α-amylose (20–
30%) and amylopectin (70–80%). Starch is degraded by enzymes amylases to lower molecular weight chains 
of fructose and maltose. Starch-based polymers have been selected as good biomaterials due to their 
biocompatibility and degradability [92]. Furthermore, starch is highly available, cheap and can be easily 
modified. In most relevant studies starch has been blended with other polymers to produce composite 
materials with improved properties for tissue engineering scaffolds [93, 94]. Recently, it has been 
demonstrated that starch-based fibers permit adhesion of endothelial cells, an indicator of the ability to 
permit vascularization [95]. These results confirm again the potential of these materials for tissue 
engineering. 
 
Hyaluronan, also known as hyaluronanic acid (HA), is a naturally occurring non-sulfated glycosaminoglycan 
(GAG) and is obtained from the extracellular matrix of most connective tissues such as cartilage, vitreous of 
the human eye, umbilical cord and synovial fluid [96]. Hyaluronan is a linear polysaccharide composed of N-
acetylglucosamine and glucuronic acid, linked by β(1→3) bonds. In the ECM of connective tissues, HA has 
many physiological roles, including maintaining tissue morphologic organization, structural and space-filling 
properties, and transporting ions, solutes, and nutrients [96]. Three types of enzymes have been found in 
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mammals which may participate in the enzymatic degradation of HA: (1) hyaluronidase, (2) b-D-
glucuronidase, and (3) b-N-acetyl-hexosaminidase. The in vivo degradation time of unmodified HA varies 
from few minutes in blood to hours or days in skin [97, 98]. The degradation products of HA are 4–20 
disaccharides in length which display angiogenic properties, stimulating capillary growth, endothelial cell 
proliferation and migration [99, 100]. Interestingly, HA inhibits the adhesion and aggregation of platelets, 
and these nonthrombogenic properties are of particular importance in cardiovascular tissue engineering 
[101]. HA was used for the luminal surface coating of vascular grafts [102]. Hyaluronan has been used for 
different tissue engineering applications [103-105], most likely due to the fact that it is a macromolecule of 
the ECM, thus mimics the native environment during tissue development.  
1.2.2.2 Natural proteins: Collagen, Gelatin, and Fibrin 
With respect to protein-based polymers, collagen, fibrin, and gelatin will be described in more detail in the 
following sections. Protein-based polymers have the benefit of mimicking many features of ECM and thus 
have the potential to control migration, growth and organization of cells during tissue regeneration process. 
 
Collagen molecules have a triple-helical structure and provide high tensile strength due to the arrangement 
of triple helices in fibrils. This biopolymer is the major protein component of the ECM and plays a dominant 
role in maintaining the biologic and structural integrity. There are four main collagen types (I, II, III, and V) 
that make up the essential part of collagen in bone, cartilage, tendon, skin, and muscle [106, 107]. The most 
explored collagen for biomedical applications is collagen type I. Collagen scaffolds have been investigated for 
blood vessels, heart valves and ligaments [108]. The possible degradation by human collagenases makes 
collagen an ideal scaffold for tissue engineering and could potentially lead to the restoration of tissue 
structure and functionality [109]. The degradation rate often needs to be regulated using diverse methods 
such as crosslinking techniques [110]. A variety of formats including porous sponges [111], gels and sheets 
[112, 113], and foams [114] have been investigated by using bioresorbable collagen. The feasibility of TEVGs 
made of collagen and cells was first demonstrated in 1986 by Weinberg and Bell [115]. Despite the low 
degradation rate, collagen has the distinctive drawback that the availability of homologous (human) collagen 
is very low as it is difficult to obtain from patients.  
 
Gelatin is derived from collagen and formed by breaking the natural triple-helix structure of collagen into 
single-strand molecules by hydrolysis. Gelatin is less immunogenic compared with its precursor. It is 
commonly used for pharmaceutical and medical applications due to its biodegradability and biocompatibility 
in physiological environments [116]. Additionally, cell adhesion, migration, differentiation and proliferation 
can be presumably promoted due to the existence  of informational signals like the Arg–Gly–Asp (RGD) 
sequence [117, 118]. Gelatin blended with chitosan has been used in artificial skin and cartilage applications 
because of the ability to form a polyelectrolyte complex [119]. Li et al. published that bioengineered cardiac 
Chapter 1 
26  
 
grafts can be fabricated by fetal cells and 3D gelatin mesh [120]. Interestingly, spontaneous contraction was 
observed in-vitro as well in-vivo. Nevertheless, histological analysis could not confirm the identity of the cells 
[120]. 
 
Fibrin is a biopolymer of the monomer fibrinogen, meaning it is the end-product of the coagulation cascade 
following the conversion of fibrinogen in the presence of thrombin and calcium [121]. Fibrinogen is a soluble 
plasma glycoprotein, which is produced by the liver. Fibrin and fibrinogen play essential roles in blood 
clotting, fibrinolysis, cellular and matrix interactions, the inflammatory response, wound healing, and 
neoplasia [121]. Fibrin is used as a naturally-occurring scaffold that can be produced from the patient’s own 
blood and used as an autologous scaffold without the potential risk of a foreign body reaction [122].  Based 
on their autologous and bioresorbable properties, many applications for tissue engineering has been 
established in combination with cells, growth factors, or drugs [123-125]. The most broadly used forms of 
fibrin scaffolds are fibrin hydrogels, fibrin glue, and fibrin microbeads  [126]. Fibrin vascular constructs are 
weaker and more extensible than collagen-based constructs. Therefore mechanical properties can be 
improved by fibrin-collagen composites presenting higher strength than collagen alone, but also more gel 
compaction [127]. Interestingly, fibrin gels can stimulate SMC to synthesize elastin, which is an important 
component of arteries [128]. However, fibrin hydrogels display three major disadvantages: the shrinkage of 
the gel, low mechanical stiffness, and its rapid degradation before proper formation of tissue engineered 
structures [123, 129]. On the other hand, as fibrin is known to degrade within several days by cell-associated 
enzymatic activities, it can be utilized for the controlled release of growth factors [130]. Moreover, by adding 
for example aprotinin, that restricts or even stops fibrinolyse, the degradation can be controlled [129]. 
Aprotinin is a monomeric serine protease inhibitor found to effectively inhibit the activity of several 
proteases, including plasmin, trypsin, chymotrypsin, and kallikrein [131]. 
1.2.2.3 Decellularized Extra Cellular Matrix (ECM) 
Besides using proteins, such as fibrin or collagen, also the complete natural ECM has been discovered as an 
appropriate matrix for tissue engineering. The ECM works as a supporting material and regulator of cellular 
functions including cell survival, proliferation, morphogenesis and differentiation [132]. Many organs and 
tissues, such as vessel, heart valves, and pericardium from humans and animals (e.g. sheep, pigs, and rabbits) 
have been studied for use as starter matrix [133-136] and in-vivo complete cellular ingrowth was proved in 
animal models [137, 138]. However, the use of either xenogenic or allogenic ECM increases the risk for 
immunogenic reactions. Moreover, using unfixed biological material, and in particular when using xenogenic 
matrices, there is a risk of disease transmissions, such as Creutzfeldt–Jakob disease, and transmission of 
microorganisms or retroviruses [139]. Therefore, the use of both allogenic and xenogenic material to produce 
cardiovascular replacements necessitates either crosslinking or decellularization of the tissue. Crosslinking 
the extracellular matrix, however, results in a fixed, non-living and non-degrading matrix, which will not be 
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able to grow and remodel and is not suitable as a scaffold for tissue engineering. Alternatively, 
decellularization of the biological tissues decreases the immunological response without limiting the 
remodeling capacity, which in turn favorably impacts the long-term graft durability [140]. Various 
decellularization methods for extracellular matrix are developed and documented [141-144], aiming at the 
removal of all cellular and nuclear matter while reducing any effects on the integrity and structure of the 
remaining ECM to preserve the biomechanical characteristics of the native graft [145, 146]. Complete cell 
removal from the tissue is crucial, as residual cells and cell remnants within the matrix might lead to 
calcification [147]. Nevertheless, the clinical efficacy of commercially available materials has already been 
largely positive despite small amounts of remaining DNA [148]. Biological scaffold materials, from which most 
or all visible cellular material is removed, are suggested to be safe for implantation [143]. It should be noticed 
that the best method for removing all cellular remnants (meanwhile leaving the extracellular matrix intact) 
might be different from the most favorable treatment with respect to in-vitro or in-vivo repopulation of the 
matrix. This because a small pore size, low porosity, and higher density of the collagen network restrict the 
(seeded) cell adhesion, migration and proliferation [149, 150].  
1.3 Myocardial tissue engineering 
It is common medical knowledge that every injury in the myocardium results in an irreversible functional 
deficit as the cardiac muscle has no major potential to regenerate itself. This loss of functional muscular 
tissue reduces the global work and pumping efficiency of the heart [151]. When the pumping efficiency of 
the heart is impaired and it cannot pump a sufficient amount of blood to meet the metabolic requirements 
of the body, which eventually leads to a heart failure. The single most common cause of left-sided cardiac 
failure is ischemic heart disease followed by acute myocardial infarction. Unfortunately, current 
interventional or drug therapies cannot adequately control disease progression and eventually heart 
transplantation is the only treatment option for end-stage heart failure [152]. Due to the widespread lack of 
organ donors and complications associated with immunosuppressive treatments new strategies to repair the 
injured cardiac muscle are being investigated leading to the development of several approaches for 
myocardial tissue engineering in the last decade. In general the field of “cardiac tissue engineering” or 
“myocardial tissue engineering” aims at restoring the structural and functional damage of the myocardium 
by use of different techniques and approaches. Overall, “cardiac tissue engineering” comprises the following 
individual techniques and/or combinations thereof: i) transplantation of cells and/or stem cells aiming at 
cellular integration or cell-mediated tissue repair, ii) transplantation of in vitro engineered contractile 
myocardial tissue constructs aiming at their full functional integration, and iii) mobilization of endogenous 
cells and / or stem cells that induce intrinsic repair phenomena [152-154]. In addition, several approaches 
have focused on injecting mechanical stabilizers without cells, such as hydrogels, in order to stabilize the 
myocardial scar and to prevent wall aneurysms and to reduce wall motion abnormalities [155]. As part of 
this chapter we will mainly focus on the second approach (ii) as this is the only one, where biomaterials 
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combined with cells will be involved. We will briefly review the materials used in the in vitro engineering of 
the myocardial tissue. 
Myocardial tissue represents one of the most complex tissues of the human body and therefore one of the 
most difficult ones to engineer in vitro. This fact and the ease of harvest have stimulated approaches using 
biological tissues as scaffolds for myocardial regeneration [152]. Robinson et al., pioneered this field using 4-
layer multilaminate urinary bladder-derived extracellular matrix constructs for the in vivo integration as full 
thickness left ventricular cardiac patches showing in vivo population with contractile cells as well as rapid 
biodegradation of the matrix. In a direct comparison with synthetic scaffolds, such as expanded 
polytetrafluoroethlyene (ePTFE), the native tissue-derived matrices showed superior results [156]. One 
major obstacle of synthetic tissues was the absence of the typical highly ordered anisotropy present in the 
native cardiac extracellular matrix, which seems essential to proper myocardial function. Recently, 
Engelmayer et al. successfully recapitulated this cardiac anisotropy in vitro for synthetic scaffolds using 
microfabrication techniques to create an accordion-like honeycomb microstructure in polyglycerol sebacate 
matrices. After culture with neonatal rat cardiomyocytes the engineered matrices showed mechanical 
properties similar to the native myocardium [157]. In contrary to these studies, several groups have focused 
on engineering myocardial tissues in vitro even without using any extracellular matrix substrate at all. One 
approach is the use of cell sheet engineering and cell stacking techniques for the development of contractile 
cell sheets in vitro. Initially, Shimizu et al. generated pulsatile cardiac tissue grafts via layering of neonatal rat 
cardiomyocyte cell sheets and stacking to form multilayer sheets [158]. Later studies [159-161] reported the 
successful in vitro manufacture of vascularized multilayered constructs [160] as well as improved ejection 
fraction and beneficial left ventricular remodeling after injection in vivo [161]. Similar to these studies the 
creation of micro-tissue building blocks using the hanging-drop technique for the repair of myocardial tissues 
has been evaluated extensively in recent years [162, 163]. Recently, the approach has been expanded to 
different human cell and stem cell sources and principal feasibility was demonstrated after in vivo injection 
into the border zone of the ischemic myocardium in a porcine model [164, 165]. Taken as a whole, the above 
reported studies create hope for a potential realization of in vitro engineered functional myocardial 
replacements in the future. However, when considering the previously mentioned significant progress in the 
field of vascular tissue engineering with first in-human trials and the long phases of preclinical development, 
it becomes clear that cardiac tissue engineering is in its fledgling stage and many hurdles remain to be 
surmounted before concrete clinical therapies will evolve. 
1.4 Vascular tissue engineering 
The structural design of the scaffolds is a key issue in engineering living vascular substitutes. On the one hand 
it has to endure the cyclic stresses and strains exerted upon implantation and on the other hand it is also the 
basis for the seeding cells, an anchor to attach different bioactive molecules and signals. The ideal graft 
should have and maintain the same compliance as a normal artery and should be flexible and maintaining its 
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contour. Cell infiltration into the scaffold is one of the prerequisites for successful tissue regeneration and is 
primarily determined by the scaffold microstructure, i.e. pore size and fiber thickness [166]. Additionally, the 
microstructure of the scaffold can affect cell phenotype and influences the behavior of the infiltrating cells 
regarding cell adhesion, spreading, and proliferation [167]. It is also used as an anchor to attach different 
bioactive molecules and signals that improve specific cell function, such as, pro-angiogenic signals [168]. 
Finally, “off-the-shelf” availability in various sizes and lengths for emergency care plays an important role, 
and its handling characteristics should include operative suturability and simplicity of surgical handling. 
1.4.1 Polymeric starter matrices in vascular tissue engineering 
Different materials have been reported for vascular tissue engineering (table 1), either natural origin, 
including decellularized matrices [133-135] or collagen [115], or synthetic polymers, such as PET [169] or PGA 
[58]. Natural-based polymers display no toxic degradation or inflammatory reactions and can be produced 
from biological sources. On the other hand, synthetic polymers present a higher strength and durability 
compared to natural polymers, but the bulk degradation might result in local inflammation. Thus, choosing 
a scaffold material is a critical step in successful vascular tissue engineering. The first TEVG, which was created 
in 1986 by Weinberg and Bell [115]. They generated cultures of bovine endothelial cells, smooth muscle cells 
(SMCs) and fibroblasts in layers of collagen gel. However, as the burst pressure of these TEVGs was very low, 
a polyethylene terephthalate (PET) mesh was added to enhance the burst pressure [115]. During the 
following years several studies have been conducted to improve the strength of collagen-based constructs 
by incorporating cells, matrix components, and intracellular biomolecules [170-172]. Girton et al. used 
glycation to stiffen and strengthen collagen gel construct [173]. Furthermore, un-degradable or degradable 
meshes were used as matrices [174-176], as well as the utilization of dynamic mechanical stimulation [177]. 
In 1998, Shinoka et al. reported surgical implantation of TEVGs in lambs, in which scaffolds were constructed 
from autologous myofibroblasts and endothelial cells seeded onto PGA grafts [57]. This study demonstrated 
the first vascular graft using autologous cells that yielded a viable structure [57]. In the same year, L’Hereux 
and coworkers published the generation of a functional blood vessel without a scaffold [178]. Tissue sheets 
were generated by culturing human SMC and skin fibroblasts to overconfluency and then were fused around 
a mandrel to generate mechanically robust vessels [178]. This tubular structure mimicked a native artery and 
displayed a burst pressure of 2594mmHg. However, blood infiltration between vessel layers was observed. 
One year later Niklason et al. reported the use of PGA scaffold tube seeded with SMC and ECs which was 
cultured in a bioreactor under flow conditions [58]. Histologic examination of the TEVG presented the vessel 
wall homogeneously colonized by SMCs. Furthermore, engineered vessels displayed measurable 
contractions in response to serotonin and prostaglandin. The grafts were patent in vivo up to 4 weeks of 
observation [58]. Another interesting study based on synthetic biomaterials was published by Dahl et al. They 
used a PGA scaffold which was seeded by SMCs and subsequently cultured in a bioreactor that delivers cyclic 
radial strain [179]. After culture period vascular grafts were decellularized to remove antigenic cellular 
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material and then implanted into baboons as arteriovenous (AV) conduits in nonhuman primates [179]. This 
study leads to the first U.S. implant of engineered human artery, decellularized allogenic grafts were 
implanted as AV conduits in few patients with kidney failure [180], which is still ongoing. However, Shinòka 
and colleagues reported already in 2001 the first application of a TEVG in human [181]. They seeded cells 
from patient`s peripheral vein on a tubular scaffold made from polycaprolactone-polylactic acid copolymer 
that was reinforced with PGA. The TEVG was subsequently implanted as a pulmonary artery graft into the 
patient and seven months after implantation, TEVGs were still functional, without complications or aneurysm 
[181]. Based on success of this study further tissue engineered constructs were implanted, either as 
extracardiac total cavopulmonary connections or as tissue engineered patches [182, 183]. There were no 
complications such as thrombosis or stenosis and all TEVG presented an adequate flow.  
Campbell and coworkers reported to grow vessels similar to natural arteries using the in-vivo tissue 
engineering approach, namely by implanting a silastic tubing into the peritoneal and pleural cavities of 
animals [19, 20]. Although the produced tissue capsule contained myofibroblasts and was covered by a 
confluent layer of mesothelial cells, these tubes were rich only in collagen. Collagen provides tensile strength 
to arteries however, in order to maintain continual pulsatile flow and avoid dilatation, elastin is an essential 
component [184]. Furthermore, these fibrocollagenous tubes which were formed in-vivo are relatively 
avascular and thus may decrease exchange between cells and blood after intravascular implantation. 
1.4.2 Cell sources for vascular tissue engineering 
The basic strategy for vascular tissue engineering includes the design and the production of convenient 
scaffolds and an appropriate cell choice for cell adhesion, proliferation, and differentiation. Obviously, the 
first investigated cell sources for vascular tissue engineering were the non-immunogenic autologous 
endothelial cells (ECs) and smooth muscle cells (SMCs), see also Table 1. ECs are indispensable to maintain 
vessel wall permeability barrier and to regulate coagulation. ECs serve as mediators of inflammation and 
additional other physiological processes [185]. Importantly, ECs are the key element to prevent thrombosis 
in small-diameter vascular grafts and prevent the development of pseudointimal hyperplasia by (i) releasing 
nitric oxide (NO) and prostacyclin (PGI2) and (ii) producing tissue-type plasminogen activator (t-PA) [101]. 
Weinberg and Bell published the construction of a TEVG with cultured bovine aortic ECs, SMCs and adventitial 
fibroblast [115]. Despite these blood vessels structurally mimicked a native artery, they lacked the functions 
of native arteries due to the burst pressure was very low. Niklason et al. also developed a TEVG based on 
bovine SMC and ECs seeded onto PGA [58]. Histological analysis displayed that the constructed wall was 
homogeneously colonized by SMCs. Whatever, McKee et al. supposed that the limiting factor of in vitro TEVG 
is the restricted proliferative capacity of adult SMCs [4]. They infected human SMCs with human telomerase 
reverse transcriptase subunit (hTERT) to avoid SMCs ageing [4]. However, safety is still a problem due to the 
genetic manipulation. Over time alternative cell sources for vascular tissue engineering have become more 
important. For example, Levenberg and coworkers described the differentiation steps of human ESCs into 
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ECs forming tube-like structures on matrigel and forming microvessels containing mouse blood when 
transplanted into servere combined immune deficiency (SCID) mice [30]. Cho et al. used bone marrow 
derived ECs and SMCs from canine to engineer small-diameter vascular grafts in vitro [186]. Interestingly, 
Shinòkas` and Matsumuras` groups have also used bone marrow derived cells to repair vessel defects in 
canine as well as in patients [187-189]. Another study demonstrated the construction of an elastic vessel wall 
in small diameter using SMCs differentiated from human ASCs [190]. Therefore, the SMCs were seeded in 
PGA unwoven mesh and following subjected to pulsatile stimulation in a bioreactor for 8 weeks. The 
engineered vessel wall presented a dense and well-organized structure similar to that of native vessels [190]. 
 
1.5 Heart valve tissue engineering 
Tissue-engineered heart valves (TEHVs) are proposed as alternative valve replacements to overcome the 
limitations of current substitutes. Of the three aforementioned tissue-engineering approaches, the in-vitro 
and the in-situ approach are extensively investigated for development of heart valve replacements using 
various scaffold materials and cell sources (as listed in Table 2). The third in-vivo tissue-engineering approach, 
that relies on autologous tissue formation, has also been applied for heart valve engineering by 
intraperitoneal implantation of either a fixated bovine pericardial pulmonary valve scaffold [16] or mold in 
the shape of a tri-leaflet valve  [17, 18]. However, this approach faces an unbalanced volume fraction of 
cellular phenotypes, resulting in inadequate remodeling of the valves [191].  
1.5.1 Polymeric starter matrices in heart valve tissue engineering 
Different types of scaffold material, as introduced in the sections before, are used for heart valve tissue 
engineering. The scaffold for valve replacement that comes closest to the geometry and structure of the 
native valve with native-like mechanical and physiological hemodynamics, is the xenograft or allograft 
(homograft) valve. Obviously, the allograft valve is a more natural option compared to the xenograft valve, 
as the ideal valve replacement should show similar biomechanical characteristics to the native heart valve. 
Natural leaflet motion and flow patterns are supposed to avoid stress related calcification and early valve 
failure [140]. The microstructure of the allograft valve is favorable with respect to proliferation, 
differentiation, and survival of reseeded cells [144]. The availability of the allograft valve, however, is limited 
by donor shortage. Due to its anatomic similarity to human valves, the porcine heart valve represents an 
attractive alternative to allograft valves. Additionally, also xenogenic pericard is investigated as material for 
valve replacements [192]. However, xenografts are associated with the risk of immunogenic reactions or 
disease transmission and the availability of homografts is limited [193]. To eliminate immune reactions with 
xenogenic tissues, they are decellularized before implantation [194] and are either reseeded prior to 
implantation [195, 196] or expected to become repopulated in-vivo. Although the latter was demonstrated 
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in animal models [21, 197-199], clinical studies led to contrary reports about cellular infiltration in humans 
[200-204].  
To overcome the limitations of xeno- and homografts, the applicability of various bioresorbable polymers, 
either synthetic (such as PGA, P4HB and PCL) and natural materials (such as fibrin and collagen) was 
investigated (Table 2). Seeded with (autologous) cells and subsequently cultured in-vitro, these materials 
have shown to be feasible for heart valve tissue engineering, with demonstrated functionality in-vitro and 
in-vivo [164, 165, 205-214]. For example autologous myofibroblast and ECs (or neonatal human dermal 
fibroblast) have been used to create fibrin-based TEHVs and have been evaluated in sheep up to 3 months. 
Although the leaflets remodeled in-vivo, the retraction of the leaflets resulted in valvular insufficiency 
therewith hampering the valve functionality [211, 212, 215, 216]. Also the synthetic bioresorbable polymer 
PGA showed promising results when combined with P4HB or PLLA [208, 213, 217-219]. When seeded with 
autologous myofibroblasts, mesenchymal stem cells (MSCs), and ECs valves can be engineered in-vitro that 
undergo structural and functional remodeling in-vivo without stenosis. However, also in these valves 
functionality was hampered by trival to moderate regurgitation after 6 weeks due to thickening and 
retraction [213][214]. 
1.5.2 Cell sources for heart valve tissue engineering  
In the native heart valve, valvular interstitial cells ensure the maintenance of the living tissue with the 
capability to grow and repair. The two most important functions of these cells are to replicate and to 
synthesize and remodel the extracellular matrix [220]. Therefore, to prevent in-vivo deterioration, a living 
valve replacement with regeneration capacity is pursued. It is, however, unclear whether there is a need for 
a living tissue at time of implantation, or whether circulating cells in the blood or cells from adjacent tissues 
will be able to repopulate a scaffold in-vivo [203, 204]. Although accumulating evidence suggests that 
circulating endogenous cells can be recruited in-vivo in animal models [21, 197-199], clinical studies led to 
contrary reports about cellular infiltration in humans. Although a single case of complete repopulation of the 
vessel wall and partial repopulation of the distal part of the leaflet was demonstrated recently [200], others 
observed only sparsely cellular infiltration in the wall [201, 202] and leaflets [203] of decellularized valve 
tissues implanted in humans. Acellular xenograft valves implanted in children resulted in dramatic structural 
failure, due to a strong inflammatory response without signs of cell repopulation or endothelialization of 
either the valve leaflets or the conduit wall [204]. Thus, for clinical application it might be required to preseed 
the scaffold prior to implantation, or to modulate the scaffold in order to attract the proper endogenous cells 
in-vivo. Moreover, preseeding may also be necessary to reduce thrombogenicity and reduce the 
inflammatory reaction. 
While it is still unclear whether there is a need for a living implant at the time of implantation, a variety of 
cell types have been described for in-vitro (re)seeding of synthetic or biological scaffolds, as summarized in 
Table 2. Experiments comparing allogenic and autologous cells demonstrated that the seeded cells should 
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be of autologous source to minimize the immune response [163]. However, it was recently shown that also 
autologous cells can provoke an immune response caused by pro-inflammatory cytokines originating from 
cell death, or DAMP molecules released by dying cells within the autologous tissue [193, 221]. 
Vascular derived myofibroblasts and endothelial cells can be harvested from the recipient saphenous vein 
[222]. Alternatively, cells derived from bone marrow or umbilical cords (blood) and the circulating endothelial 
progenitor cells show the potential to provide both interstitial and endothelial function and are successfully 
used to generate heart valves in-vitro Hoerstrup [208, 217-219]. In contrast to vascular cells, these cells can 
be obtained without surgical intervention, thereby enabling potential adaption into in a routine clinical 
scenario.  
It is clear that the most appropriate cell type for in-vitro preseeding is not established yet. Bone marrow 
derived MSCs are attractive candidates. These cells are successfully used to reseed decellularized matrices 
[144, 223] or synthetic scaffolds [208, 209, 224]. MSCs show a remarkable similarity in phenotype compared 
to valvular interstitial cells [225] and demonstrate anti-thrombogenic [226] and immunosuppressive 
properties [227]. These cells are favorable for utilization in routine clinical practice, due to their ease of 
accessibility and handling and their use in allogenic application [228]. Additionally, both the anti-
thrombogenic properties of the MSCs [226] and the ability to stimulate in-vivo endothelialization [229], 
overcome the necessity of preseeding with endothelial cells. Moreover, MSCs are able to differentiate into 
endothelial cells, fibroblasts or myofibroblasts, and smooth muscle cells [144]. Alternatively, scaffolds 
(re)seeded with MSCs just prior to implantation, have been successfully implanted in sheep and baboons 
[223, 230]. Instead of proliferation, differentiation, and extracellular matrix production in-vivo, MSCs may 
induce the homing and differentiation of autologous host cells, through a paracrine secretion of growth and 
chemotactic factors enabling tissue regeneration [231]. 
1.6 The challenges in bench to bedside research  
1.6.1 Challenges and limitations in vascular tissue engineering 
Despite the variety of accepted biomaterials for clinical applications and successful in-vitro studies for TEVGs, 
just few reports describe the effective transplantation of tissue-engineered vascular grafts into human 
patients. In 2001, Shinòka`s group performed the first clinical study using vascular cell-seeded bioresorbable 
polymer scaffolds (PGA or PLLA 50:50 copolymer ε-caprolactone) in the high-flow low-pressure pulmonary 
venous system of pediatric patients [181]. Seven months after implantation, TEVGs were still functional, 
without complications or formation of aneurysms [181]. Nevertheless, few patients showed TEVG stenosis, 
which was successfully treated with angioplasty [232]. L`Heureux`s group generated a complete autologous 
in-vitro grown TEVG without a scaffold and implanted these grafts in 10 hemodialysis patients with end-stage 
renal disease and hemodialysis failure [233]. However, in three cases the TEVGs failed due to thrombosis 
and/or formation of an aneurysm [233]. Both clinical studies demonstrated encouraging results; however, in 
the both studies the technologies and autologous cell systems involved are associated with significant 
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amounts of logistical and regulatory complexity. Therefore, an off-the-shelf alternative would be desirable 
that could be produced and stored in large numbers and is available for a large number of patients. A 
potential solution is offered by clinical trials which have been recently started in Poland and the USA, based 
on PGA scaffolds seeded with SMCs [179, 180]. After culture in a bioreactor, decellularized allogenic grafts 
were implanted as AV conduits in patients with kidney failure [180] and these trials a still going on. These 
decellularized grafts can be stored for longer periods and did not cause significant immune response in 
primates [179]. Also other groups have focused on this approach using different scaffolds and 
decellularization techniques. In these studies the fast in vivo cellular repopulation evident in the generated 
matrices was highly interesting [33, 70, 234]. Also for this approach preclinical trials have been performed 
[33, 70, 234]. However, more sophisticated studies are warranted and an optimal standardized protocol has 
to be defined by future studies on the way to the clinical realization of the technology. 
1.6.2 Challenges and limitations in heart valve tissue engineering 
Translation of the completely autologous living TEHVs into clinics faces several challenges such as the ethical 
and logistic hurdles to overcome with the isolation, culture and use of autologous cells. Therefore, the 
feasibility and functionality of these autologous living valves, created according to the classical tissue-
engineering paradigm, have only been demonstrated in animal studies. One of the limitations for this 
approach is cell-mediated contraction of the valve leaflets caused by traction forces exerted by the cells. On 
the one hand, this cell-mediated contraction is functional in ensuring the development of a desirable, highly 
aligned extracellular matrix [211, 215, 235-237]. However, on the other hand sustained traction forces 
exerted by the cells may damage the tissue and restrict culture time, but shorter culture times limit collagen 
and elastin deposition [211]. Furthermore, in valvular tissue-engineering, sustained traction forces can lead 
to undesirable retraction of the leaflets, which results in valvular regurgitation [163, 164, 212-215]. It has 
been suggested to avoid the valvular insufficiency by creating longer leaflets, therewith enlarging the 
coaptation area [215, 238], engineering bi-leaflet valves instead of tri-leaflet valves [211, 238], or applying a 
bioresorbable support material within the fibrin scaffold [212]. As the observed retraction is mainly cell-
mediated, others applied the myosin inhibitor blebbistatin to the TEHV prior to implantation [215]. Although 
this transiently blocked further cell-induced tissue contraction initially, leaflet retraction reoccurred beyond 
4 weeks follow-up in the ovine model. It can be concluded that a proper solution to control these retraction 
forces is lacking and it remains a challenge to overcome retraction of the tissue engineered leaflets. The 
cellular stress generation in tissue engineered constructs demonstrated to comprise both a passive and 
active contribution of the cells [239]. Therefore, retraction of the tissue-engineered leaflets may be 
prevented by removal of the cellular components. Besides overcoming the cell-mediated retraction of the 
leaflets, decellularization of the TEHVs enables off-the-shelf availability of the valve replacement [33] 
demonstrating promising results both in sheep and non-human primate models [70, 240]. Moreover, in these 
studies also another challenge in the field of heart valve tissue-engineering was tackled, namely the 
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combination with novel minimally invasive implantation procedures. Although new catheter based 
implantation techniques are rapidly evolving, the current valve substitutes applicable for these techniques 
are bioprosthetic in origin, consequently lack repair-, remodeling- and growth capacity, and therewith are 
restricted to the use in elderly patients. Recently, it was demonstrated that the vulnerable living engineered 
tissues withstand the necessary crimping of the stented valve replacement to make them suitable for 
minimally invasive implantation techniques [214, 241, 242], therewith opening the way towards the 
translation of these minimally invasive replacement techniques also for children and young adults. 
The first clinical implementation of TEHVs was performed with decellularized pulmonary allograft valves, 
reseeded with autologous endothelial progenitor cells, showing improved freedom from re-intervention in 
contrast to conventional homografts and xenografts. They demonstrated low gradients in follow-up and 
possibly exhibited adaptive growth (interpreted from the increasing diameter of the tissue-engineered 
pulmonary valve annulus and reduction of valve regurgitation) [195]. Decellularized allograft valves, 
reseeded with autologous vascular endothelial cells, demonstrated uncompromised follow-up of 10 years, 
with excellent hemodynamic performance [196]. However, the need for valve replacements exceeds the 
supply of donor valves. Therefore, also the largely available decellularized xenogenic pulmonary valves, 
reseeded with autologous vascular endothelial cells, have been introduced for right ventricular outflow tract 
reconstruction, with excellent early and midterm results [243]. Moreover, the short- and mid-term 
performance of non-seeded decellularized xenograft valves in children and patients with congenital heart 
disease were recently reported to meet the performance of other currently available implants [200]. 
Nevertheless, as mentioned earlier, the first clinical non-seeded applications in children resulted in dramatic 
structural failure of the heart valves, due to strong inflammatory responses [204]. Additionally, complete 
destruction of a decellularized pulmonary xenograft valve was reported in a single case [244]. 
1.7 Conclusions  
For the in-vitro manufacture of cardiovascular bioengineered constructs several different materials have 
been used over the last decades. Besides the use of surface treated or modified native tissues, also natural 
and fully synthetic polymer scaffolds have been used to serve as a basis for tissue engineering processes. As 
the scaffold plays a crucial role in successful designing of tissue engineering constructs, the choice of material 
directly influences the outcome. Natural-based polymers display no toxic degradation or inflammatory 
reactions and can be produced from biological sources. On the other hand, the main advantage of synthetic 
polymers is certainly the chance to actively control the polymer composition and therefore to modify the 
durability, strength, and biodegradation behavior of the deriving constructs. The main advantage of complete 
natural matrices represents the unique functional characteristics currently only present in native tissues. 
Composite biomaterials have the potential to overcome the current predicament of having to choose 
between either synthetics or natural tissues. Therefore, despite a variety of materials have been validated, 
future effort should focus on perfecting composite materials to take full advantage of the best properties. 
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So far, scientists in the field of heart valve tissue engineering have not been able to create synthetic matrices 
with the same unique functional characteristics of a native heart valve. The latest bioengineered heart valve 
constructs still lack the heterogenous anisotropic microstructural organization of the native tissue, and 
thereby inferior to the very distinct physiological function of the native valve with contractile elements in 
systole and durable load bearing behavior in diastole. Moreover, they do not contain all components of the 
native leaflets and lack the microstructural elements presents in the native-analogous organization. This 
amplifies that as long as natural tissues are superior to synthetic scaffolds in terms of functional behavior, 
the use and clinical translation of synthetic polymer matrix-based tissue engineered cardiovascular 
constructs remains to be rather future hope than scientific reality. On the other hand, given the widespread 
scarcity of donor organs and the immunological, infectious as well as ethical hurdles of cross-species 
transplants, only synthetic or human derived natural off-the-shelf products hold the potential to offer 
therapeutic solutions for the tremendously increasing numbers of cardiovascular patients worldwide. This 
implies that scientists will and have to stay committed to designing improved polymeric starter matrices for 
the replacement of cardiovascular tissues. However, it seems essential that future synthetic scaffolds not 
only copy native tissues in their composition of structural components, but also duplicate their 
microstructural organization. In the coming decades research will most likely focus on intelligent, off-the-
shelf scaffolds that make use of the regenerative capacity of the human body by attracting endogenous cells. 
Obviously, long-term (pre-clinical) studies are compulsory to evaluate the remodeling of these optimized 
materials towards native like tissues. Nevertheless, bioresorbable scaffolds have large potential to eventually 
replace the use of the current synthetic and fixed-biological grafts and function as therapeutic replacement 
structures in the future. 
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1.8 Aim of the study 
Tissue engineering (TE) is a discipline with the intention to repair, replace or regenerate injured tissues and 
organs. The three essential elements of in vitro TE comprise i) the cells that are seeded onto the graft, ii) the 
scaffold onto which the extracellular matrix forms, and iii) the biological and mechanical stimuli that promote 
new tissue formation and maintenance. Over the last decades TE has made great strides forward and 
different scaffold materials and cell sources have been validated with a main focus on their therapeutic 
potential for regenerative medicine. In combination with TE, stem cells are associated with a number of 
promises in further advancing contemporary medicine. An ideal cell source for human therapeutic and 
disease modeling applications should be non-immunogenic, functional, and easy to isolate and expand. 
Therefore, induced pluripotent stem cells from human peripheral blood are a promising source for 
establishing robust, patient-specific tissue models for studying the pathogenesis of vascular disease as well 
as for developing novel therapeutic applications based on in-vitro TE. 
While the engineered living substitute develops, the biocompatible scaffold should degrade without leaving 
remnants in the body, requiring a so-called biodegradable starter matrix (scaffold). Synthetic polymers have 
been extensively used for TE, given their high durability, flexibility, and mechanical strength. Additionally, 
production conditions of synthetic polymers can be tightly controlled, hence making mechanical and physical 
properties of the material predictable, reproducible and precisely defined . These characteristics make 
synthetic polymers to an interesting raw material for scaffold fabrication. 
Therefore, the aim of the studies contained in this thesis is to (a) compare three commonly used synthetic 
polymers (P4HB, PLA, and PCL) for in-vitro TE applications under static and dynamic conditions, (b) reprogram 
and characterize peripheral blood mononuclear cells (PBMCs) into hiPSCs, (b) differentiated and characterize 
hiPSCs into smooth muscle cells and endothelial cells for in-vitro tissue engineering, (c) assess and compare 
the tissue-enginneered vascular grafts cultured under static and dynamic conditions. 
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Table 1: Tissue-engineering of vascular grafts: scaffold materials, cell sources, (pre-) clinical studies, and 
main conclusions. 
Scaffold Cell source (& 
in-vitro culture 
period after 
seeding, if 
applicable) 
(Pre-) 
clinical 
study  
(follow-up 
period) 
Conclusions and references 
 
Synthetic materials 
  
PGA Bovine SMC and 
EC 
Miniature 
swine (up 
to 24 days) 
In-vivo, lack of mature elastin and polymer 
remnants [245] 
Autologous 
myoFBs and EC 
In lambs 
(up to 24 
weeks) 
In-vivo, growth and development of 
endothelial lining and ECM [246] 
Human SMC 
(decellularizatio
n after culture) 
In 
nonhuman 
primates 
(up to 6 
months) 
In-vivo, arteriovenous conduits, can be stored 
at least 12 months, no aneurysmal dilatation, 
no calcification, no substantial intinam 
hyperplasia, clinical trial followed [247] 
 
Canine SMC 
(decellularizatio
n after culture) 
In canine 
(up to 12 
months) 
In-vivo, excellent long-term patency, no 
stenosis or dilatation, no intimal hyperplasia 
[247] 
Human SMCs; 
Pulsatile 
stretching, 
decellularizatio
n 
In human AV shunts for dialysis (ClinicalTrials.gov 
Identifier: NCT01744418 and NCT01840956) 
PGA+PHA bovine carotid 
artery cells 
In lambs 
(up to 5 
months) 
In-vivo, remained patent, no aneurysms [142] 
PGA+P4HB Lamb vascular 
cells 
In lambs 
(up to 100 
weeks) 
In-vivo, growth and remodeling capacity of  
implants, no thrombus, calcification, stenosis, 
or aneurysm [248] 
PCL-PLA 
polymer 
with PGA 
Autologous BM-
MNC, no culture 
In human Extracardiac cavopulmonary conduits [249-
251] 
PCL n.a. In rats (up 
to 18 
months) 
In-vivo, no aneurysm, no calcification, 
polymers remnants [211] 
 
n.a. In rats (up 
to 18 
months) 
In-vivo, until 6 months: perfect patency, after 6 
months: regression [252] 
 
Natural materials 
  
Fibrin Lamb SMC  In-vitro, two-layer grafts, SMCs only in inner 
layer [15] 
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Human dermal 
FB 
 In-vitro, entrapment of FB in fibrin gel, burst 
pressures (1400-1600 mmHg) and compliance 
comparable to native arteries [253] 
Collagen Bovine SMC, 
FBs and EC 
 In-vitro, mimicked a native artery, burst 
pressure very low [254] 
Chitosan Rabbit vascular 
SMC 
 In-vitro, proper swelling property, burst 
strength: 4000mmHG, high suture-retention 
strength [255] 
Collagen/ 
elastin 
tubular 
scaffolds 
Human vascular 
SMC 
 In-vitro, circumferential orientation of SMCs 
was uniformly distributed [256] 
 
Biological decellularized materials 
  
Human 
umbilical 
artery 
  In rat (up 
to 8 
weeks) 
In-vivo, 5 rats died within few hours after 
implantation (thrombosis), 6 TEVGs remained 
patent [257] 
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Table 2: Tissue-engineering of heart valves: scaffold materials, cell sources, (pre-) clinical studies, and main 
conclusions. 
Scaffold Cell source (& 
in-vitro culture 
period after 
seeding, if 
applicable) 
(Pre-) 
clinical 
study  
(follow-up 
period) 
Conclusions and references 
 
Synthetic materials 
  
PHA Autologous 
myoFB and EC 
In sheep 
(up to 17 
weeks) 
In-vivo functionality with minimal 
regurgitation; laminated fibrous tissue with 
predominant glycosaminoclycans [207]. 
PLA & 
PLGA  
Human dermal 
FB and bovine 
aortic EC or 
ovine myoFB 
and EC (2 
weeks) 
n.a. In-vitro p.o.p. of human TEHV [247]. 
P4HB Autologous  
vascular medial 
and EC (8 days) 
In sheep 
(up to 24 
weeks) 
In-vivo functionality of viable leaflets without 
thrombus; with mild, non-progressive valvular 
regurgitation [258]. 
Human UC-
blood-DPC (3 
weeks) 
n.a. In-vitro generation of viable TEHV from 
CD133+ cells [219]. 
PGA Ovine 
(autologous) 
myoFB and EC 
(>2 weeks) 
In sheep 
(up to 11 
weeks) 
In-vivo p.o.p. of TEHV based on synthetic 
scaffolds; no stenosis; trivial (autografts) and 
moderate (allogenic valves) regurgitation; 
suggest superiority of autograft tissue [163, 
164]. 
PGA & 
P4HB 
Human myoFB 
and EC (4 
weeks) 
n.a. In-vitro p.o.p. of TEHV for systemic application 
[71]. 
Human marrow 
stromal cells (3 
weeks) 
n.a. In-vitro p.o.p. of TEHV based on human MSC 
[208]. 
Human UC-DPC 
(3 weeks) 
n.a. In-vitro p.o.p. of TEHV based on human 
umbilical cord-derived progenitor cells [259]. 
Human 
amniotic fluid 
derived 
progenitor cells 
(3 weeks) 
n.a. In-vitro p.o.p. of TEHV based on human 
amniotic fluid derived progenitor cells [217]. 
Ovine MSC (3 
weeks) 
n.a. In-vitro p.o.p. of TEHV based on ovine MSC 
[224] 
Ovine 
peripheral 
blood EPC (3 
weeks) 
n.a. In-vitro p.o.p. ovine peripheral blood EPC as 
single cell source for TEHV [218]. 
Autologous 
myoFB and EC 
(3 weeks) 
In sheep 
(up to 20 
weeks 
In-vivo functionality; mobile leaflets no 
stenosis, thrombus, or aneurysm; remodeling 
towards native valves in microstructure, 
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mechanical properties, and extracellular matrix 
[205]. 
Autologous 
myoFB and EC 
(up to 4 weeks) 
In sheep 
(up to 8 
weeks) 
In-vivo p.o.p. of trans-apical implantation of 
TEHV; in-vivo pulmonary functionality with 
mobile, but thickened leaflets [214]. 
Autologous 
MSC,  cultured 
4 weeks) 
In sheep 
(up to 8 
months) 
In-vivo p.o.p. of TEHV based on MSC, with 
trival to mild regurgitation at implantation and 
remodeling towards native valves [209]. 
Autologous 
bone marrow 
stromal cells 
In non-
human 
primates 
(up to 4 
weeks) 
In-vivo p.o.p. of minimally invasive one-step 
approach (isolation, seeding, and subsequent 
implantation); remodeling to endothelialized 
anisotropic tissues [230]. 
Autologous 
bone marrow 
stromal cells 
In sheep 
(acute 
study) 
In-vivo p.o.p. of trans-apical implantation of 
TEHV in the systemic circulation [260]. 
PGA & 
PLLA 
Autologous 
MSC (1 month) 
In sheep 
(up to 20 
weeks) 
In-vivo functionality with trival to moderate 
regurgitation after 6 weeks due to thickening 
and retraction; valves undergo structural and 
functional remodeling without stenosis [213].  
PCL n.a. n.a. In-vitro p.o.p of functionality of electrospun 
scaffolds [261, 262]. 
Human myoFB 
(3 weeks) 
n.a. In-vitro testing of knitted scaffold for TEHV 
shows low seeding efficiency, but better 
strength compared to electro -spun scaffold 
[263]. 
 
Natural materials 
  
Fibrin Neonatal 
human dermal 
FB (3-5 weeks) 
In sheep 
(up to 8 
weeks) 
In-vitro p.o.p. for aortic pressures, and in-vivo 
p.o.p. of fibrin-based TEHV with increasing 
regurgitation (trival to moderate) at 4 weeks; 
at 8 weeks complete retraction hampered 
functionality [211, 215, 216]. 
Autologous 
myofibroblast 
and EC (4 
weeks) 
In sheep 
(up to 3 
months) 
In-vivo p.o.p. of fibrin-based TEHV with 
remodeling leaflets, but retraction resulted in 
valvular insufficiency [212]. 
Fibrin & 
poly-l-
lysine 
Human myoFB n.a. In-vitro p.o.p. of fibrin-based TEHV, external 
fixation is required to control leaflet retraction 
[264]. 
Collagen FB (up to 8 
weeks) 
n.a. In-vitro p.o.p. of TEHV based on directed 
collagen gel shrinkage [252]. 
 
Biological decellularized materials 
  
Human 
pulmonary 
valve 
n.a. In human SynerGraft treatment reduced tissue antigen 
expression but did not alter biomechanics or 
strength; lack of panel reactive antibody 
response [137]. 
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n.a. In human 
(up to 5 
years) 
Moderate regurgitation; showed improved 
freedom from explantation, and low gradients 
compared to xeno- and homografts [195]. 
Autologous 
vascular EC  
In human 
(up to 10 
years) 
Excellent hemodynamic performance during 
mid-term follow-up. Biopsy of wall reveled 
recellularization [196, 202, 243, 255]. 
Autologous EPC 
(3 weeks) 
In 2 
children 
(up to 3,5 
years) 
Good functionality with decreased 
regurgitation (mild to trival) and increased 
pulmonary annulus diameter [265]. 
Human 
aortic valve 
  In human Low transvalvular gradients similar to 
conventional homografts, but with low panel 
reactive antibody response [266]. 
Ovine 
pulmonary 
valve 
  In sheep 
(up to 11 
months) 
In-vivo proof of completely endothelialization 
(after 6 months) and up to 80% leaflet 
recellularization with interstitial cells after 11 
months (with expression of α-SMA similar to 
native valve leaflets); no calcification; no 
regurgitation  [137, 197, 198, 267, 268]. 
  In sheep 
(up to 1 
year) 
In-vivo recellularization of basal region of cusp 
with myoFB; no calcification; trivial 
regurgitation [138]. 
With or without 
autologous EC 
(5 days) 
In sheep 
(up to 6 
months) 
In-vivo endothelialization and partially cellular 
infiltration of leaflets; no regurgitation or 
calcification; no difference between seeded 
and non-seeded groups [267-269]. 
Autologous 
myoFB and EC 
(8 days) 
In sheep 
(up to 3 
months) 
In-vivo functionality; complete 
endothelialization; no calcification of valve 
[206]. 
Ovine 
aortic valve 
  In sheep 
(up to 9 
months 
In-vivo incomplete endothelialization of leaflet; 
cellular infiltration in wall and very sparse in 
leaflet; no calcification [270]. 
Porcine 
pericardiu
m 
n.a. In rat (up 
to 6 
weeks) 
In-vivo PGG-treated pericardium did not 
calcify; infiltration by host FB with subsequent 
matrix remodeling [113]. 
Human MSC (8 
days) 
n.a. In-vitro p.o.p. of layered fibrous and spongiosa 
scaffolds (pericardium and pulmonary artery) 
[192]. 
Porcine 
pulmonary 
valve 
  
n.a. In human 
children 
Structural valve failure between 7 days and 1 
year due to strong inflammatory responses; no 
repopulation [204]. 
n.a. In human 
(up to 5 
years) 
Valve performance superior to currently 
available implants; no calcification [200]. 
Autologous EC In human  
(up to 5 
years) 
Excellent hemodynamic performance; no 
calcification; no difference compared to 
allogenic decellularized valves [243]. 
Autologous 
myofibroblast 
and EC (16 
days) 
In sheep 
(up to 4 
weeks) 
In-vitro and in-vivo p.o.p. of TEHV for 
percutanous implantation; in-vivo 
functionality; expression of α-SMA in leaflets 
[241, 271, 272]. 
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Autologous 
bone marrow 
mononuclear 
cells or MSC, 
injected prior to 
implantation 
In sheep 
(up to 4 
months) 
In-vivo endothelialization and cellular 
infiltration in both groups; valve calcification, 
thickening, retraction and inflammation in 
BMMC group; thin leaflets, no calcification, 
lower transvalvular gradients and remodeling 
towards native valves in MSC group [223]. 
Porcine 
aortic valve 
n.a. Subdermal 
in rat (up 
to 6 
weeks) 
In-vivo calcification was reduced by TRI-COL / 
nuclease treatment [141]. 
n.a. In sheep 
(up to 5 
months) 
In-vivo proof of functionality untill 
explantation; ingrowth of host fibroblastoid 
cells; no calcification [197]. 
Human vascular 
EC (3 days) 
n.a. In-vitro p.o.p. of TEHV by seeding 
decellularized matrices [273]. 
Human MSC (4 
weeks) 
n.a. In-vitro proof of human MPC to infiltrate 
acellular porcine valve matrix under static 
conditions; reseeded cells also expressed 
osteogenic markers [274]. 
Human 
neonatal 
dermal FB (8 
weeks) 
n.a. In-vitro proof of gradual population of 
accelular matrix with viable cells that produce 
matrix [275]. 
 
 
Abbreviations used in table 1&2 
Scaffold Cell source Others 
P4HB = poly-4-hydroxybutyrate 
PHA = polyhydroxy-alcanoates 
PGA = polyglycolic acid 
PLA = polylactic acid 
PLGA = copolymer of  
PGA and PLA 
PCL = polycaprolactone 
FB = fibroblasts 
EC = endothelial cells 
MSC = mesenchymal stem cells 
EPC = endothelial progenitor cells 
UC-DPC = umbilical cord – 
derived progenitor cells 
n.a. = not applicable 
p.o.p. = proof of principle 
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2.1 Introduction 
 
During the last years, the interdisciplinary field of tissue engineering (TE) has emerged as a platform for the 
development of biological substitutes. The overall goal is the repair and/or regeneration of tissues or organs 
to resolve major health related concerns in humans. Multiple disciplines, such as cell biology, biomaterial 
research and biomedical engineering  have contributed to the advances of tissue engineering technologies. 
Any tissue engineering approach is composed of three major components: (1) cells, (2) biocompatible 
scaffolds, and (3) suitable biochemical (e.g. growth factors) and physical (e.g. cyclic mechanical loading) 
stimuli supporting tissue formation in vitro and in situ [1]. While the engineered living substitute develops, 
the biocompatible scaffold should degrade without leaving remnants in the body, requiring a so-called 
biodegradable starter matrix (scaffold).  
A variety of synthetic biodegradable polymers has been investigated as TE scaffold materials, though the 
main disadvantage of these materials is their lack of functional groups [2, 3]. This results in limited capacity 
to combine with bioactive elements to reinforce their cell affinity [3]. In general, functional synthetic 
polymers have unsaturated bonds [4], or functional groups such as hydroxyl [5], carboxyl [6], and amide [7], 
through which functional biomaterials can be chemically modified by biomolecules to improve their 
bioactivity [5]. Nonetheless, synthetic polymers have been extensively used for TE, given their high durability, 
flexibility, and mechanical strength [8]. In addition, production conditions of synthetic polymers can be tightly 
controlled, hence making mechanical and physical properties of the material predictable, reproducible and 
precisely defined [9]. These characteristics make synthetic polymers to an interesting raw material for 
scaffold fabrication [8-10].  
In particular, poly-glycolic acid (PGA), poly-lactic acid (PLA), poly-hydroxy alkanoate (PHA), poly -caprolactone 
(PCL) and their deriving copolymers have generated substantial interest as scaffold materials for the in vitro 
TE of bone, cartilage, as well as cardiovascular tissues [11-14]. PGA is most commonly used because it 
degrades at predictable time point and into (generally) biocompatible components [8]. Besides, the high 
porosity of PGA meshes permits a good diffusion, neovascularization and cellular infiltration [15]. 
Unfortunately, PGA meshes are biodegraded rapidly within few weeks and can therefore not withstand 
mechanical forces exerted to the materials and guide the shape of the bioengineered construct over longer 
culturing periods [15, 16]. As a result, hybrid polymers have been designed in order to combine the shape-
memory and mechanical stability of slowly degrading polymers with the fast degrading properties of 
polymers, such as PGA [17]. For instance, combinations of PGA with polymers such as (poly-4-
hydroxybutyrate) P4HB or PLA have been widely explored [8, 13, 14, 18, 19]. PLA is synthesized by 
polymerization of lactic acid and can be eliminated through the citric acid cycle [15]. Due to the chiral nature 
of PLA, several distinct forms are existing: poly-L-lactide (PLLA), poly-D-lactide (PDLA) and LD racemic 
(PDLLA), respectively [15]. PLA can easily be processed and its degradation rates and physical/mechanical 
  Different Hybrid-polymers for Tissue Engineering 
 61 
 
characteristics are adjustable over a wide range by using different molecular weights and copolymers [19, 
20]. Also ε-caprolactone and copolymers have been studied intensely and are frequently investigated for 
biomedical applications [15]. Interestingly, PCL degrades very slowly in-vivo via enzymatic degradation and 
hydrolysis [21]. Unlike PGA and PCL, which are synthetized using chemical methods, P4HB is produced 
naturally by microorganisms making it more challenging to be synthesized [22]. After implantation into the 
body, P4HB degrades mainly by bulk hydrolysis producing 4HB, a normal component of the mammalian body 
[10].  
In 1998, Shinoka et al. reported surgical implantation of tissue engineered vascular grafts (TEVGs) in lambs, 
in which scaffolds were constructed from autologous cells seeded onto PGA grafts [23]. Further studies have 
been conducted, for instance, by using PGA-poly-L-lactic acid (PLLA) scaffolds for microvessels in mice [24] 
or scaffolds composed of polyglycolide knitted fiber, and an L-lactide and ε-caprolactone copolymer sponge 
for TEVGs in a canine inferior vena cava model [25]. The hybrid polymeric scaffold fabricated from either PGA 
or PLA fiber-based mesh coated with a 50:50 copolymer of L-lactide and ε-caprolactone (PCLA/PGA or 
PCLA/PLA) are more elastic than the PGA scaffold [26]. This results in an improved compliance match 
between the vessel and the conduit and ultimately in better surgical handling characteristics [26]. For both 
heart valve and vascular tissue engineering the use of PGA meshes coated with P4HB, meaning the 
combination of the thermoplastic characteristic of P4HB and the high porosity of PGA meshes, has been 
investigated intensively with promising results in vitro and in preclinical studies [27-29]. In 2006, Hoerstrup 
et al. provided the first evidence of living, functional pulmonary arteries engineered from vascular cells 
seeded on PGA/P4HB scaffolds in a growing lamb model [13]. In contrast, PCL has been mainly investigated 
for biomedical applications in bone and cartilage repair, as surgical suture as well as for drug delivery systems, 
especially those with longer working lifetimes [12, 15]. Lee et al. showed that a PCL/ poly(methyl 
methacrylate) (PMMA) scaffold was suitable for cell growth in vitro and for new bone formation in vivo [30]. 
This study suggested that PCL/PMMA blends can be used for biopolymer composite scaffolds in bone tissue 
engineering [30]. In general, all polyesters are biocompatible and have formed the bases of numerous FDA 
approved medical devices for clinical use [9, 31]. 
However, in spite of their frequent use in biomedical research and therapeutic products, there is still a lack 
of systematic comparative analyses, such as qualitative and quantitative assays of tissue formation and 
biomechanics between different synthetic polymers. Therefore, the present study aims at a systematic, 
multimodal comparison of three frequently used polymers (PGA, PLA, PCL) integrated into a co-polymer 
solution with P4HB for the in vitro engineering of extracellular matrix under static as well as dynamic 
conditions. These data might allow for a specific selection of a certain polymer starter matrices aiming at 
specific tissue properties of bioengineered materials in vitro. 
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2.2 Material and Methods  
 
2.2.1 Isolation and culture of human umbilical cord fibroblasts 
Human umbilical cords (n=3) were collected after full-term births with informed consent according to 
the cantonal ethics commission of Zurich, Switzerland [KEK-ZH-2009-0095] and processed for isolation 
of venous fibroblasts according to established protocols [32]. Briefly, the umbilical cord vein was 
isolated surgically and small tissue pieces were cut out using a dissecting scissors. Tissue pieces were 
placed on a sterile petri dish and were left to adhere to the bottom for 20min. Culture medium 
containing DMEM high glucose (Sigma-Aldrich, Switzerland), 10% fetal bovine serum (Biowest, USA) 
and an antibiotic/antimitotic solution (Sigma-Aldrich, Switzerland), was gently added and changed 
every third day. Tissue pieces were removed after first cellular outgrowth after approximately 1-2 
weeks of incubation under humidified incubator conditions at 5% CO2 at 37 °C. Three different 
fibroblast cell lines (named B014, B015 and B020) were isolated.  
 
2.2.2 Phenotyping of human fibroblasts 
Isolated human cells (n=3) were characterized using immunofluorescence staining for common 
myofibroblast markers. Therefore, cells were cultured on 3.5 cm2 cell culture dishes, fixed with 4% 
paraformaldehyde (Sigma-Aldrich, Switzerland), and incubated over night at 4°C with the following 
primary antibodies: alpha smooth muscle actin (1A4, Abcam, United Kingdom), Vimentin (Vim 3B4, 
Abcam, United Kingdom), CD90 (EPR3133, Abcam, United Kingdom), CD31 (JC70A, Dako, USA), and 
Phalloidin (Life Technologie, Switzerland). The following secondary antibodies were used: anti mouse  
Alexa Flour 488 (Invitrogen, USA) and anti rabbit Alexa Flour 488 (Invitrogen, USA) and Dapi (Sigma-
Aldrich, Switzerland). Cells were analyzed with a DM6000B fluorescence microscope (Leica, Germany). 
Image processing was performed using the Leica software (Leica, Germany). 
 
2.2.3 Proliferation assay 
Cellular proliferation was assessed by determining the number of total cells based on the absorbance 
of crystal violet when cultured on a 24-well plate for up to 7 days. In brief, every day cells were fixed 
with methanol (Sigma-Aldrich, Switzerland) for 10 minutes and stained with 0.1% crystal violet 
(Artechemis, Switzerland) for 5 minutes. The 24-well plates were washed and air-dried. Cells were 
solubilized with 2% Na-deoxycholat (Sigma-Aldrich, Switzerland) while being heated at 60°C for 10min. 
The absorbance was analyzed at 550nm using a standard ELISA reader Synergy HT (Bio TEK, USA). To 
obtain quantitative information a standard curve with serial dilutions was performed.  
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2.2.4 Surface morphology of biomaterials 
Samples were mounted on electron imagining stubs using carbon tape and subsequently sputter 
coated in 5nm of Pt/Pd (Quorum Technologies, EMS 300TD, USA) to reduce fiber degradation during 
imaging. A field emitting electron microscope was used to image samples at 15 kV power (Zeiss, FESEM 
Ultra Plus) for clarity. For each sample, four regions of interest (ROI) measuring 1000 x 800 um were 
imaged from which five fibers per ROI were measured using Image J software (NIH, v1.48s, line tool) 
to determine the average fiber diameter of an ROI. For scaffold porosity, an additional four ROIs 
measuring 3000 x 2250um were imaged. Each porosity ROI image was then automatically thresholded 
in Image J and porosity was defined as the percent area that was non-fiber (ie empty/porous space).   
 
2.2.5 Tissue Engineering 
 
2.2.5.1 Scaffold fabrication 
Patches were fabricated from non-woven polyglycolic acid (PGA) meshes (thickness 1.0 mm; specific 
gravity 70 mg/cm3; Cellon, Luxembourg) and coated with either 1% poly-4-hydroxybutyrate (P4HB; 
TEPHA, Inc., USA) or 1% Poly(L-lactide (PLA, Carbion, USA) or 1% polycaprolactone (PCL, Carbion, USA) 
by dipping into a tetrahydrofuran solution (Sigma-Aldrich, Switzerland). After solvent evaporation and 
vacuum drying overnight, the scaffolds were placed into a 70% EtOH (Sigma-Aldrich, Switzerland) for 
30 min to obtain sterility, followed by two washing cycles with PBS (Sigma-Aldrich, Switzerland). 
Thereafter, scaffolds were pre-incubated in DMEM culture medium previously described for 12–24 
hours to facilitate cell attachment. 
 
2.2.5.2 Cell seeding 
Human fibroblasts (n=3) were seeded onto scaffolds using a density of 1.5*106cells/cm2. Therefore, 
fibrinogen (Sigma-Aldrich, Switzerland) (10 mg/mL of active protein) and thrombin (Sigma-Aldrich, 
Switzerland) were prepared, used and titrated to an optimal clotting time of approximately 30sec by 
adapting the concentration of fibrinogen. The cells were resuspended in a fibrinogen-thrombin co-
solution and subsequently seeded onto the sterile scaffolds. After static incubation of seeded 
constructs in DMEM (10% fetal bovine serum; penicillin/streptomycin and 0.9mM of L-ascorbic acid-
2-phosphate (Sigma-Aldrich, Switzerland)) for 7 days, they were kept either under static conditions or 
placed onto a shaker for additional mechanical stimulation via shear stress. The constructs were 
harvested after 21 days of culture and processed immediately for subsequent analyses 
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2.2.6 Qualitative Tissue Analysis 
For immunohistochemical analysis of TE patches (n=3 per group), sections with 5µm thickness derived 
from blocks of formalin-fixed, paraffin-embedded tissue were mounted on glass slides (SuperFrost 
Plus, Menzel Gläser,Germany), deparaffinized, rehydrated and stained with hematoxylin and eosin 
(H&E) or Masson Trichrome using standard histological techniques. All sections were analyzed using a 
Mirax Midi BF slide scanner (Zeiss, Germany) and processed using MIRAX viewer (Zeiss, Germany).  
 
2.2.7 Quantitative Tissue Analysis 
TE patches (n = 6 per group) were minced, lyophilized, and analyzed using biochemical assays for total 
deoxyribonucleic acid (DNA) content as an indicator for cell number, hydroxyproline (HYP) content as 
an indicator for collagen, as well as for glycosaminoglycan (GAG) content. All TE patches were digested 
in papain (Sigma-Aldrich, Switzerland) solution (300 µg/mL in PBS with 5mM EDTA (Sigma-Aldrich, 
Switzerland) and 5mM cysteine (Sigma-Aldrich, Switzerland), at 65°C for 16 hours. For measuring the 
cellularity of the constructs, the DNA amount was quantified according to manufacturer’s protocol 
(Life Technologies, Switzerland, No. P11496). The GAG content was determined using a modified 
version of the protocol described by [33], and a standard curve prepared from chondroitin sulfate from 
shark cartilage (Sigma-Aldrich, Switzerland). Hydroxyproline was determined with a modified version 
of the protocol provided by [34]. Remnants of the hybrid polymers matrices were visualized using 
polarization microscopy (Zeiss, Germany). 
 
2.2.8 Biomechanics 
After 0 (only for the unseeded group) and 21 days of culture, the mechanical properties of the TE 
constructs (n = 4 per group) were assessed using a uniaxial tensile tester (Instron 5864, Boston, MA, 
USA) equipped with a 100-N load cell. For comparison, native tissues (cartilage, skin and vein) were 
harvested from sheep post mortem provided by the local slaughterhouse Zurich/Hinwil, Switzerland 
(n=4). The crosshead speed was set to correspond to an initial strain rate of 7mm/min and the tester 
operated at 5bars of air pressure. Patches had a cross-sectional area of 14mm x 4mm x 1 mm (length 
x width x thickness) and were fixed with hydraulic clamps. Stress–strain curves were obtained and 
Young’s modulus was determined as the slope of the curve at a strain of 10%, as a measure for tissue 
stiffness. 
 
 
 
2.2.9 Statistic 
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Quantitative data are presented as mean ± standard deviation. For statistical comparison of the 
proliferation rate of the three different cell lines a one-way ANOVA was performed and p-values < 0.05 
were considered statistically significant. Surface morphology measurements were statistically 
analyzed by non-parametric Mann-Whitney-U-test and p-values < 0.05 (corrected post hoc according 
to Bonferroni) were considered statistically significant. In addition, quantitative tissue analysis and 
biomechanics were statistically evaluated by an unpaired students-t-test and p-values p < 0.05 
(corrected post hoc according to Bonferroni) were considered statistically significant. KS normality test 
was used to confirm normal distribution of the dataset (p > 0.05). All statistical analyses were 
performed using the GraphPad Prism 5 software (GraphPad Software Inc., USA). 
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2.3 Results 
 
2.3.1 Phenotype and proliferation of umbilical cord derived fibroblasts 
Immunofluorescence performed on fibroblasts derived from three different patients revealed that all cell 
types displayed similar immunophenotypic patterns. Isolated human fibroblasts expressed myogenic 
markers, such as alpha smooth muscle actin and vimentin, and common fibroblast marker CD90 (Figure 1a). 
 
Figure 1: Phenotypic characterization and proliferation of isolated fibroblasts.  
a) Immunohistochemical analyses of three different human fibroblast cell lines (B014, B015 and B020) revealed positive expression 
of alpha smooth muscle actin, Vimentin and CD90 (Phalloidin in red, Dapi in blue and respective antibody in green). All three markers 
showed a homogenous expression pattern. Fibroblasts were negative for the endothelial cell surface marker CD31. b) Cell number 
was determined over one week for all three cell lines using the crystal violet-based proliferation assay. No significant differences 
were detected. (Scale bars: 50 µm)  
 
In contrast, the cells were negative for the endothelial cell surface marker CD31 excluding non-fibroblastic 
contamination during cell isolation procedures. In the proliferation analysis based on crystal violet staining 
(Figure 1b), no significant differences in proliferation parameters were detected between the three fibroblast 
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lines when considering cell numbers over 7 days (p<0.05). These findings exclude potential significant inter-
individual proliferation differences. 
 
2.3.2 Surface morphology of biomaterials 
Microstructural analysis using scanning electron microscopy (SEM) was used to analyze the fiber size and 
porosity of unseeded polymers before and after coating (Figure 2a-d and f-i) (n=4 per condition). 
 
Figure 2: Surface and intersection morphology of biomaterials. Scanning electron micrographs (SEM) show the fiber alignment and 
size of unseeded biomaterials. a-d) SEM of the surface f-i) SEM of the cross section e) The fiber diameter was consistent among all 
biomaterials. (n=4) j) PGA-PCL was significantly less porous than PGA-P4HB or PGA-PLA. PGA-P4HB and PGA-PLA showed a similar 
porosity. (n=4) (Scale bars: 100 µm)  
 
The PGA-PCL matrix (Figure 2a and f) was less porous in comparison to the hybrid polymers PGA-P4HB (Figure 
2b and g), PGA-PLA (Figure 2c and h), and PGA (Figure d and i). Quantitative measurements of the porosity 
confirmed these differences (Figure 2j). PGA-PCL scaffolds were significantly less porous than PGA-P4HB 
(p<0.05) or PGA-PLA (p<0.05) scaffolds. PGA-P4HB and PGA-PLA scaffolds showed a similar porosity with no 
significant difference (p=0.69). Uncoated PGA mesh was significant more porous in comparison to PGA-P4HB 
(p<0.05), PGA-PLA (p<0.05), and PGA-PCL (p<0.05). The fiber diameter was uniform among all biomaterials 
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with no statistically significant differences between different hybrid polymer groups or uncoated PGA (Figure 
2g, p<0.05) (Figure 2e). Imaging of the surface (Figure a-d) and cross section (Figure f-i) display the 
distribution of the coating compared to PGA scaffold only. The different hybrid polymer present a similar 
distribution of the coating. In general, there was more coating visible on the outer scaffold regions, while in 
the central part of the scaffold less was detected. 
 
2.3.4 Qualitative Tissue Analyses 
Microstructural features of human fibroblast-derived TE patches were analyzed by histological staining 
procedures (Figure 3) as well as polarization microscopy (Figure 4).  
 
Figure 3: Histology of tissue-engineered patches under static and dynamic conditions. Hematoxylin-eosin (H&E) staining of statically 
cultured tissue-engineered patches (left column) revealed cellular ingrowth with tissue formation, and some collagen fibers could be 
detected with Masson Trichrome staining (MT). In contrast, patches cultured under dynamic conditions (right column) demonstrated 
more cellular tissue formation and production of extracellular matrix elements. All three cell lines displayed similar tissue formation 
for respective conditions/coatings. PGA-PCL patches showed for both culture conditions less tissue formation and high quantities of 
scaffold remnants in comparison to PGA-P4HB or PGA-PLA. (Scale bars: 200 µm) 
 
H&E staining demonstrated formation of extracellular matrix (ECM) in vitro with high cellularity and layered 
tissue on the outer scaffold regions, while in the central part of the scaffold low cellularity and no significant 
formation of ECM were present. In order to investigate the deposition of collagen fibers Masson Trichom 
  Different Hybrid-polymers for Tissue Engineering 
 69 
 
staining was used. In general, TE patches under dynamic conditions (Figure 3, right column) revealed more 
tissue formation and ECM deposition compared to static conditions. 
Importantly, all three cell lines exhibited comparable tissue formation for respective hybrid polymer 
conditions excluding a potential bias due to inter-individual differences. PGA-PCL-based patches showed for 
both culture conditions (dynamic and static) less tissue formation and high quantities of scaffold remnants 
in comparison to the PGA-P4HB or PGA-PLA. In order to confirm these findings polarization microscopy was 
performed to further visualize different polymer components (Figure 4).  
 
 
 
Figure 4: Polarization microscopy of tissue-engineered patches under static and dynamic conditions. Polarization microscopy 
revealed the presence of the initial scaffold matrix in particular in the central part of the constructs. PGA fibers are shown as 
elongated ellipses (high magnification). Webbings between PGA fibers represent coating remnants (low magnification). However, in 
the dynamic fibroblast-based constructs the biomaterial remnants were more degraded (d-f) compared with static cultures (a-c).  
PGA-PCL (b, e) starter matrix showed a very strong preservation of the co-polymer when compared to PGA-P4HB (a, d) or PGA-PLA 
(c, f) scaffolds (scale bars: 400µm low magnification, 100 µm high magnification). 
 
The starter matrices showed no major remodeling in the central part of the constructs in static as well as 
dynamic conditions given the lack of tissue formation in this area of the constructs. PGA fibers were visible 
as elongated ellipses (Figure 4, high magnification), whereas the webbings between PGA fibers represented 
remnants of the coating (Figure 4, low magnification). In dynamic conditions the biomaterial was more 
degraded (Figure 4d-f) when compared to the static cultures (Figure 4a-c). In particular, the PGA-PCL starter 
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matrix (Figure 4b, e) showed strong preservation of the polymer components compared to PGA-P4HB (Figure 
4a, d) or PGA-PLA (Figure 4c, f). 
 
2.3.5 Quantitative Tissue Analysis 
The composition of the ECM of the human fibroblast-derived TE constructs was biochemically analyzed using 
assays for HYP, GAG, and the cell number (DNA) (Figure 5).  
 
 
Figure 5: Extracellular matrix analysis of tissue-engineered patches under static and dynamic conditions. Extracellular matrix 
analysis shows the amount of hydroxyproline (HYP), glycosaminoglycans (GAG), and the cell number (deoxyribonucleic acid, DNA) of 
tissue-engineered patches, which were statically or dynamically cultured (all values relative to control samples (ctrl) indicating 
biomaterials only). Generally, all three cell lines displayed similar amounts of HYP, GAG and DNA for respective conditions/coatings, 
no significant differences were detected. Overall PGA-P4HB (n=6) showed a higher expression of DNA, GAG, and HYP in comparison 
to PGA-PLA (n=6) or PGA-PCL (n=6).  
 
 
The expression level of DNA, GAG, and HYP is for all 3 coatings higher under dynamic conditions than under 
static conditions. Analyses were performed after three weeks of static or dynamic culture. In general, no 
significant differences were detected between the three different cell lines relating to expression of HYP, 
GAG and DNA for respective coatings under static or dynamic conditions, indicating no inter-individual 
differences. In total, six TE patches per cell line and per coating condition were analyzed. PGA-P4HB showed 
a significantly higher expression of DNA, GAG, and HYP in comparison to PGA-PLA (p<0.05) or PGA-PCL 
(p<0.05) under static conditions suggesting a more rapid formation of ECM in vitro. Moreover, PGA-PLA 
exhibited a significantly higher expression of DNA and HYP than PGA-PCL (p<0.05) under static conditions. 
Dynamically cultured PGA-PLA (p<0.05) and PGA-P4HB (p<0.05) patches expressed a significantly higher 
amount of DNA, GAG and HYP than PGA-PCL patches. PGA-P4HB (p<0.05) also displayed a significantly higher 
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DNA and HYP expression than PGA-PLA. In general, the expression levels of DNA, GAG and HYP were higher 
for all coatings under dynamic conditions compared to statically cultured patches. 
 
2.3.6 Biomechanics 
The material properties of the different TE patches used in this study were determined via uniaxial tensile 
tests in comparison to native ovine tissue, such as cartilage, skin and vein (Figure 6). Stress–strain curves 
were obtained and Young’s modulus was determined as the slope of the curve at a strain of 10%, as a 
measure for tissue stiffness. Contribution of tissue formation to the mechanical properties was observed in 
all TE patches, given a higher elasticity with culture time in comparison to unseeded control. Due to the rapid 
loss of mechanical integrity of the scaffold, biomechanical tests on the TE patches under dynamic conditions 
over time could not be performed.  
  
Figure 6: Mechanical properties of tissue-engineered patches and native tissue. Stress–strain curves were obtained and Young’s 
modulus was determined as the slope of the curve at a strain of 10%, as a measure for tissue stiffness. Control (ctrl) means 
biomaterials only. Generally, PGA-PCL (n=12, 4 patches per group) showed a significant higher Young`s modulus, tensile strength and 
lower strain at maximal stress compared to PGA-PLA (n=12) or PGA-P4HB (n=12). As a comparison cartilage, skin and vein samples 
(n=4) were also tested. 
 
Overall, PGA-PLA and PGA-P4HB TE patches show similar biomechanical properties. Both conditions display 
tensile stress of about 0.02MPa and strain at maximal stress of about 20%. Tensile moduli of both 0.04MPa 
and 0.08MPa were obtained, which were not significantly different (p=0.1479). In case of PGA-PCL, tensile 
stress was 0.54MPa, tensile strain was 8%, and having a Young`s modulus of 4MPa respectively. Generally, 
PGA-PCL showed a significantly higher Young`s modulus, tensile strength and lower strain at maximal stress 
compared to PGA-PLA (p<0.05) or PGA-P4HB (p<0.05). For a better interpretation of the obtained results, 
also native ovine tissue were analyzed biomechanically. For cartilage, Young’s modulus was about 35MPa, 
tensile strength was 12MPa, and strain at maximal stress was 32.5%. In addition, skin had a Young`s modulus 
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of 0.005MPa, tensile stress of 14.5MPa and tensile strain of 160%. Similar results were found for the vein 
with a Young`s of 0.0054MPa, a tensile stress of 2MPa and tensile strain of 185%. 
 
 
  Different Hybrid-polymers for Tissue Engineering 
 73 
 
2.4 Discussion 
 
The tissue formation produced by implanted cells is highly influenced by the scaffold onto which they are 
seeded. Different types of biodegradable polymers as a scaffold have been investigated for tissue 
regeneration, such as PGA, PLA, P4HB and PCL [8, 10, 20]. Therefore, the present study aimed at a systematic, 
multimodal comparison of three frequently used polymers for the in vitro engineering of extracellular matrix 
under static as well as dynamic conditions.  
So far, most biomaterials do not completely mimic physiological microenvironment and can therefore not 
enable native like cellular interaction and behavior [15]. Blending two polymers has gathered growing 
interest for constructing native-like tissues [15]. Thus, patches were cut from PGA meshes and coated with 
same concentrations of either P4HB, PLA, or PCL. In addition, to mimic the native tissue and serving as an 
artificial environment, the structure and surface morphology of the scaffolds have to meet general 
requirements: (I) pores to ensure cell growth and nutrients/ metabolic waste transport; (II) three-
dimensional architecture; (III) suitable mechanical properties depending on the native tissue to be replaced; 
(IV) suitable surface chemistry; (V) biodegradation and bioresorbability [35]. Moreover, pore size affects cell 
binding, migration depth of cellular in-growth, cell morphology, and phenotypic expression [36].  
For this reason, we performed SEM to analyze the ultra-structure of the unseeded scaffold. SEM confirmed 
the uniform fiber diameters of the coated PGA matrix. In contrast, PGA-PCL scaffolds were significantly less 
porous than PGA-P4HB or PGA-PLA scaffolds. PGA-P4HB and PGA-PLA scaffolds showed a similar porosity. 
These findings already suggested a potential improved cell infiltration and consequent tissue formation for 
PGA-P4HB and PGA-PLA in comparison to PGA-PCL. For example, porosity of the scaffold plays an important 
role in bone and cartilage regeneration [37, 38]. Interestingly, lower porosity enhances osteogenesis by 
suppressing cell proliferation and forcing cell aggregation in vitro [38]. In contrast, higher porosity and larger 
pore size lead to greater bone ingrowths to the scaffold but diminish the mechanical properties in vivo [38]. 
However, one has to take into account that for comparative issues the concentrations of P4HB, PLA, and PCL 
were consistent and could be further adapted for specific requirements. 
Hence, microstructural features of human fibroblast-derived TE patches were analyzed by histological 
stainings as well as polarization microscopy. In general, tissue engineered patches under dynamic conditions 
represented a more extensive tissue formation and ECM deposition. Wang et al. also showed an enhanced 
cell proliferation under dynamic three-dimensional (3D) culture compared with conventional static two-
dimensional (2D) and 3D cell culture conditions [39]. In addition, high-throughput microarray analysis 
showed that gene expressions of dynamic 3D system displayed significant differences in cell proliferation and 
differentiation compared with static-2D conditions [39]. Nonetheless, PGA-PCL based patches displayed less 
tissue formation and higher quantities of scaffold remnants in comparison to the PGA-P4HB or PGA-PLA 
under static as well as under dynamic conditions.  
Chapter 2 
74  
 
In general, dynamic conditions enhanced the degradation of biomaterial in comparison to static conditions. 
In particular, less PGA fibers were detectable after 3 weeks of culture in comparison to the webbings between 
the PGA fibers, especially PGA-PCL showed particularly strong preservation of the polymer components. 
Different studies have proven that PGA degrades faster than P4HB, PLA and PCL [40, 41]. In addition, 
production conditions of synthetic polymers can be tightly controlled, hence making mechanical and physical 
properties well defined and predictable. For instance, the time to complete degradation and resorption of 
P4HB varies with size and processing, i.e., the orientation of the polymer fibers. In general, complete 
resorption of P4HB occurs between 12 and 18 months in vivo [40]. The characteristics of PLA are highly 
affected by the stereo-isomeric L/D ratio of lactate units [8]. Generally, an increased stereo-isomeric ratio 
decreases the crystallinity, whereby the degradation is enhanced. For example, degradation of PLA is faster 
than PDLA due to the lower crystallinity of PLA [8]. PLA and PCL degradation takes longer than 24 months in 
vivo [41]. In contrast, PGA is degraded within 4-6 months in vivo [15, 16]. The composition of the ECM of 
human fibroblast-derived TE constructs was analyzed and PGA-P4HB showed a significantly higher expression 
of DNA, GAG, and HYP in comparison to PGA-PLA or PGA-PCL under static conditions suggesting a more rapid 
formation of ECM in vitro. The interactions between cells and ECM are essential in cell attraction, cell 
differentiation and wound healing [42]. Dynamically cultured PGA-PLA and PGA-P4HB patches expressed a 
significantly higher amount of DNA, GAG and HYP than PGA-PCL patches. The general expression levels of 
DNA, GAG and HYP were higher for all coatings under dynamic conditions compared to statically cultured 
patches. These findings confirm and underline the findings in histology. It is proven that mechanobiological 
interactions between cells and scaffolds can crucially influence cell behavior [43-45]. For example, the 
mechanobiologic regulation of cartilage matrix biosynthesis was successfully exploited by the application of 
cyclic compression to constructs formed by encapsulating primary bovine chondrocytes in agarose hydrogels 
[45, 46]. By 28 days, determined improvements in the compressive stiffness were observed in groups that 
had been exposed to mechanical loading compared with free swelling controls [46]. Even though relations 
between these forces and cell responses are exhibited, elucidation of the mechanotransduction pathways is 
far from revealed. The transduction of external forces to signaling pathways involves intracellular forces and 
associated molecular deformations, such as gap junctions on the cell membrane, the cytoskeleton, and DNA 
[44, 45]. 
Importantly, a balance between the rate of scaffold degradation and tissue formation is crucial for 
maintaining mechanical integrity of the replaced tissues [47]. The biodegradable scaffold should have 
sufficient mechanical properties (such as strength and stiffness) approximating those of the host tissue until 
the biodegradable scaffold matrix is substituted by the new tissue [47]. The material properties of different 
TE patches used in this study were determined via uniaxial tensile tests. In addition, we compared these 
values with native ovine cartilage, skin and vein tissue. Contribution of tissue formation to the mechanical 
properties was observed in all TE patches, as samples became less stiff with culture time in comparison to 
unseeded controls. Overall, PGA-PLA and PGA-P4HB TE patches show similar biomechanical properties. 
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Generally, PGA-PCL showed a significant higher Young`s modulus, tensile strength and lower strain at 
maximal stress compared to PGA-PLA or PGA-P4HB. Meaning that on one hand PGA-PCL is stiffer and on the 
other hand is more robust than PGA-P4HB and PGA-PLA. Notably, in contrast to PGA-PCL, PGA-P4HB and 
PGA-PLA are more ductile and flexible. The values are still not in the range of native tissue but this may rely 
on the polymer remnants and the incomplete tissue formation in vitro. However, as with many polymers, 
the mechanical properties of the material depend not only on the basal material, but also on its processing 
history [40]. 
 
Conclusion 
Biodegradable synthetic polymers are an interesting raw material for scaffold fabrication and have been 
intensively investigated for TE. As the scaffold plays a crucial role in the successful design of TE constructs, 
the choice of material directly influences the outcome. Our study may allow for a specific selection of a 
certain polymer starter matrices aiming at specific tissue properties of bioengineered materials in vitro.  In 
general, we showed that PGA-P4HB coating display better tissue formation and a significant higher 
expression level of DNA, GAG and HYP in comparison to PGA-PLA and PGA-PCL. However, PGA-PCL is under 
biomechanical conditions more robust than PGA-P4HB and PGA-PLA.  
Future studies are required to evaluate, which combination under which conditions allows for the best tissue 
formation and native-like biomechanical properties. 
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3.1 Introduction 
 
Cardiovascular disease remains to be the leading cause of morbidity and mortality, accounting for 17.3 
million deaths per year worldwide [1]. Replacement of affected vascular tissues has been widely used to treat 
cardiovascular disease such as coronary heart disease, aortic aneurysm and peripheral vascular disease [2]. 
However, successful treatment of cardiovascular disease is often limited by the lack of suitable autologous 
replacement tissue. So far, expanded polytetrafluoroethylene (ePTFE), polyethylene terephthalate (PET) and 
polyurethane (PU) have been used successfully to produce synthetic vascular grafts with a diameter greater 
than 6 mm [3, 4]. Grafts smaller than 6 mm in diameter lead to many complications including acute 
thrombosis and stenosis caused by the lack of functional endothelium coverage [5]. Several approaches 
focusing on the prevention of thrombogenicity of these synthetic materials have been undertaken; in 
particular, coating of the luminal surface with heparin and other anticoagulant materials has been attempted 
with limited success [6, 7]. In addition, these grafts do not show growth-adaptive behavior, which would be 
of particular importance in children that require multiple reoperations due to the lack of growth potential 
[8]. Therefore, the current synthetic vascular replacements are suboptimal and tissue engineering (TE) is 
proposed as a solution by replacing tissues or organs with functional autologous replacement constructs. 
Tissue-engineered vascular grafts (TEVGs) represent living vascular replacement constructs, where vascular 
cells are seeded onto a three-dimensional biodegradable scaffold and then stimulated via conditioning in a 
bioreactor to promote tissue formation in vitro. However, mature vascular cells are associated with limited 
access, expansion and differentiation potential [9]. Therefore, different cell sources have been tested in 
recent years also with a focus on their use for vascular tissue engineering [10, 11]. In general, the vascular 
cell source seems to be a central problem for cell-based vascular therapies as isolated vascular cells from 
donor tissues are insufficient in quantity and show limited proliferation, extra cellular matrix (ECM) formation 
capacity, and cellular functionality following the extensive in vitro expansion process [12]. SMCs can be 
differentiated from alternative cell sources such as bone-marrow mesenchymal stem cells [13, 14], 
endothelial progenitor cells [15], or adipose-derived stem cells [16]. Nonetheless, the proliferation and 
differentiation capabilities of adult stem cells considerably decline with aging donors [17]. An interesting 
alternative is the use of human induced pluripotent stem cells (hiPSCs) which show an equivalent 
proliferation capacity, differentiation potential and gene expression similar to embryonic stem cells (ESCs). 
The main benefits of iPSCs is that they are able to differentiate into any cell type of the human body and thus 
may represent an ideal cell source for tissue engineering largely independent of the age of the respective 
donor. hiPSCs can be generated from potentially any terminally differentiated cell of the human body [18]. 
Generally, the possibility to reprogram somatic cells from a patient and generate ‘customized’ tissues from 
only few cells taken has created substantial hope in the field of regenerative medicine. The created 
autologous organs, organoids or tissues can then be transplanted back into the respective patient. 
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Furthermore, hiPSCs provide an unlimited source of proliferating cells and overcome the limitations of 
confined donor cell availability as well as limited proliferation capacity.  
Since the first iPSCs were generated from skin fibroblasts, many other sources of adult somatic cells have 
been tested for their suitability for reprogramming [18]. The use of peripheral blood mononuclear cells 
(PBMCs) isolated from peripheral blood as a source for the derivation of hiPSCs has many benefits. Firstly, 
blood collection is a minimal invasive procedure compared to a skin biopsy. Second, blood allows a minimally 
invasive large-scale isolation of sterile, viable, autologous, cellular material. A further advantage is that 
PBMCs can be reprogrammed immediately after extraction [19] whereas dermal fibroblasts need to be first 
expanded in vitro. 
 
The present study aims at the generation of TEVGs based on SMCs and ECs differentiated from PBMC-derived 
hiPSC combined with a fully biodegradable polymer matrix based on PGA and P4HB. These results pave the 
way for developing autologous vascular replacements, as well as a basis for modelling human disease in vitro 
using blood as a the only, easily accessible cell source. 
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3.2 Material and Methods 
 
3.2.1 Isolation and reprogramming of PBMC  
Human peripheral blood was collected with written informed consent according to the permission from the 
cantonal ethics commission of Zurich, Switzerland [KEK-ZH-2014-0430]. PBMCs were isolated according to 
standard protocols using Ficoll-Paque method. The reprogramming of PBMCs into hiPSCs was induced 
according to previously reported protocol [34]. Shortly, PBMCs reprogramming was achieved using viral 
vectors, which lead to the simultaneous expression of the specific transcription factors Oct4, Sox2, c-Myc 
and Klf4 (STEMCCA lentiviral vector, Boston University School of Medicine, Boston, USA). The infected cells 
were then seeded on mitotically inactivated mouse embryonic fibroblast (MEF) feeder cells and cultured in 
human iPSCs medium (DMEM/F12 (Invitrogen, Switzerland), 20% Knockout serum replacement (Invitrogen, 
Switzerland), 100mM nonessential amino acids (Sigma, Switzerland), 50mM 2-mercaptoethanol (Life 
Technologies, Switzerland), 1mM L-glutamine (Sigma, Switzerland), 50 U/ml penicillin/streptomycin (Sigma, 
Switzerland), 10ng/ml basic fibroblast growth factor (bFGF) (Life Technologies, Switzerland)). The 
reprogramming process took about 15-30 days and finally, embryonic stem like colonies were picked and 
expanded.  
 
3.2.2 Characterization of PBMC derived iPSCs 
Four different hiPSC lines were characterized using a standard series of quality controls as follows: 
x Quantitative Real-Time PCR (qRT-PCR): Total RNA was extracted using RNeasy Mini Kits (Qiagen, 
Switzerland) and reverse transcription was carried out using Superscript III RT (Invitrogen, 
Switzerland) according to the manufacturer`s instructions. qRT-PCR were performed using Rotor-
Gene SYBR Green PCR Kit SYBR (Qiagen, Switzerland) and primers for Oct4, Sox2, Nanog, Rex1, and 
Dppa3 (Microsynth, Switzerland). Reactions were run in triplicates and using standard conditions on 
a Rotor-Gene Q (Qiagen, Switzerland).  
x For detecting Alkaline Phosphatase (AP) activity, cells were fixed with 4% paraformaldehyde (Sigma-
Aldrich, Switzerland), washed with PBS and later with alkaline buffer for 10 minutes. Then alkaline 
phosphatase solution (10ml alkaline buffer containing 45µl NBT and 35µl BCP) was added and the 
reaction was stopped with TRIS-EDTA for 15 seconds. Stainings were analyzed with DMIL LED 
fluorescence microscope (Leica, Germany) and the Leica software (Leica, Germany).  
x For immunofluorescence, hiPSCs were cultured on a 3.5cm dish, fixed with 4% paraformaldehyde, 
and incubated over night at 4°C with primary antibodies (antibodies are listed in Supplemental table 
2). Staining was visualized with secondary antibodies (Supplemental table 2) for 1 hour incubation. 
Following, stainings were analyzed with DMIL LED fluorescence microscope and the Leica software. 
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x In-vitro embryoid body formation: HiPSCs were cultured in suspension in hiPSC medium without 
bFGF to form embryoid bodies (EB). After 3 weeks EB were harvested and RNA isolated for gene 
expression or plated for further differentiation (primer are listed in Supplemental table 1).  
x Teratoma assay: 2x105 undifferentiated, MEF free hiPSC were injected subcutaneously into one 
dorsal flank of NOD.CB17-Prkdcscid mice. Teratomas were analysed microscopically (histology) after 
10-12 weeks in vivo. The veterinary office of the Canton Zurich, Switzerland approved all animal 
experiments (ZH-171/2014). 
 
3.2.3 Differentiation of hiPSCs  
HiPSC were separated from MEF and cultured in suspension for 7 days in ultra-low attachment dishes 
(Corning, USA) in hiPSC medium without bFGF to form EB, which were then plated for further differentiation 
into SMCs and ECs 
 
3.2.3.1 Smooth muscle cells 
For muscle differentiation, attached EB were culture in high glucose DMEM (Sigma, Switzerland), 10% FBS 
(Sigma, Switzerland), 5% horse serum (Life Technologies, Switzerland), 100mM nonessential amino acids, 
100mM 2-mercaptoethanol, 1mM L-glutamine, 50 U/ml penicillin/streptomycin. After 14 days medium was 
changed to Smooth Muscle Growth Medium-2 (SmGM-2) (Lonza, Switzerland) and further cultured for 14 
days. All differentiated cells were fixed for immunofluorescence, lysed for total RNA extraction or further 
cultured for TE (antibodies and primers are listed in Supplemental tables 1 and 2). As a positive control 
primary human aortic SMC were commercially obtained (CC-2571;Lonza, Switzerland).  
3.2.3.2 Endothelial cells 
The differentiation of hiPSCs into ECs was induced according to previously reported protocol with some 
modifications [35]. Briefly, hiPSC were cultured in suspension for 10 days in a medium consisting of DMEM, 
20% FBS, 2mM L-glutamine, 110uM 2-mercaptoethanol, 100uM NEAA, 50ng/ml ascorbic acid, 125U/ml 
penicillin, 125mg/ml streptomycin. EBs were dissociated into single cells with 2 mg/ml collagenase B (Roche, 
Switzerland) for 2 hours then Cell Dissociation Buffer (Invitrogen, Switzerland) for 15 min at 37°C shaking at 
1,100 rpm. VE-cadherin+ cells were isolated by magnetic bead sorting (Miltenyi Biotec, USA). Isolated hiPSC-
derived ECs were plated at 20,000 cells/cm2 on fibronectin coated dishes (Corning, USA) in endothelial cell 
medium (EGM-2; Lonza, Switzerland). All differentiated cells were either fixed for immunofluorescence, or 
lysed for total RNA extraction or further cultured for TE (antibodies and primers are listed in Supplemental 
table 1 and 2). Moreover, as a positive control ECs were isolated from human umbilical cord with informed 
consent according to the cantonal ethics commission of Zurich, Switzerland [KEK-ZH-2009-0095]. 
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3.2.5 Tissue Engineering 
3.2.5.1 Scaffold fabrication 
Vessels were fabricated from non-woven polyglycolic acid (PGA) meshes (thickness 0.5 mm; specific gravity 
70 mg/cm3; Cellon, Luxembourg) and coated with 1.75% poly-4-hydroxybutyrate (P4HB; TEPHA, Inc., USA) 
by dipping into a tetrahydrofuran (THF) solution (Sigma-Aldrich, Switzerland). After solvent evaporation and 
vacuum drying overnight, the scaffolds were placed into a 70% EtOH (Sigma-Aldrich, Switzerland) for 30 min 
to obtain sterility, followed by two washing cycles with PBS (Sigma-Aldrich, Switzerland). Thereafter, scaffolds 
were pre-incubated in SmGM-2 with supplements for 12–24 hours to facilitate cell attachment. 
 
3.2.5.2 Cell seeding 
HiPSCs-derived SMCs were seeded onto scaffolds using 1.0*106cells/cm2. Fibrinogen (Sigma-Aldrich, 
Switzerland) (10 mg/mL of active protein) and thrombin (Sigma-Aldrich, Switzerland) were prepared, used 
and titrated to an optimal clotting time of approximately 30 sec by adapting the concentration of fibrinogen. 
The cells were resuspended in a fibrinogen-thrombin co-solution. After static incubation of seeded constructs 
in SmGM-2 (with supplements and 0.9mM of L-ascorbic acid-2-phosphate (Sigma-Aldrich, Switzerland)) for 7 
days, they were either placed into a bioreactor under pulsatile flow for additional mechanical stimulation via 
shear stress (dynamic condition) or kept under static conditions. The pulsatile flow was directed through the 
inner lumen and mimicked the native cardiovascular environment with an constant flow over time 
(2.5ml/min). After 21 days of culture, hiPSCs-derived ECs (1.0*106cells/cm2) were seeded into the lumen of 
TEVGs and kept for additional 3 days under static culture. The constructs were harvested after 24 days of 
culture and immediately processed for immunohistochemistry and quantitative tissue analysis.  
 
3.2.6 Qualitative Tissue Analysis 
For immunohistochemical analysis of TEVGs, 5µm sections derived from blocks of formalin-fixed, paraffin-
embedded tissue were mounted on glass slides (SuperFrost Plus, Menzel Gläser,Germany), deparaffinized, 
rehydrated and stained with hematoxylin and eosin (H&E) or Masson Trichrome using standard histological 
techniques. All sections were analyzed using a Mirax Midi BF slide scanner and processed using MIRAX viewer 
(Zeiss, Germany). In addition, immunofluorescence for αSMA and vWF were performed by IHC-Service Lab, 
University Hospital Zurich, Switzerland. Images were captured with a DM6000B fluorescence microscope 
(Leica, Germany) and processed using the Leica software (Leica, Germany). 
 
3.2.7 Quantitative Tissue Analysis 
TEVGs (n = 4 per clone) were minced, lyophilized, and analyzed using biochemical assays for total 
deoxyribonucleic acid (DNA) content as an indicator for cell number, hydroxyproline (HYP) content as an 
indicator for collagen, as well as for glycosaminoglycan (GAG) content. All samples of cell constructs were 
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digested in papain (Sigma-Aldrich, Switzerland) solution (300 µg/mL in PBS with 5mM EDTA) (Sigma-Aldrich, 
Switzerland) and 5mM cysteine (Sigma-Aldrich, Switzerland) at 65°C for 16 hours. For measuring the 
cellularity of the constructs, the DNA amount was quantified according to manufacturer’s protocol (Life 
Technologies, Switzerland, No. P11496). The GAG content was determined using a modified version of the 
protocol described by [36], as previously described, and a standard curve prepared from chondroitin sulfate 
from shark cartilage (Sigma-Aldrich, Switzerland). HYP was determined with a modified version of the 
protocol provided by [37]. Remnants of the co-polymers matrices were visualized using polarization 
microscopy. 
 
3.2.8 Statistical analyses 
Quantitative data are presented as mean ± standard deviation. Quantitative tissue analysis were statistically 
evaluated using an unpaired students-t-test and p-values p<0.05 were considered statistically significant. 
Post-hoc correction was performed using the Bonferroni method where applicable. Kolmogorov-Smirnov 
normality test was used to confirm that the datasets were normally distributed (p>0.05). All statistical 
analyses were performed using the GraphPad Prism 5 software (GraphPad Software Inc., USA). 
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3.3 Results 
 
3.3.1 Characterization of human PBMC derived iPSCs  
PBMCs were isolated from human peripheral blood using Ficoll-Paque method and reprogramming into 
hiPSCs was induced according to previously reported protocol [25] by simultaneous transduction of viral 
vectors containing Oct4, Sox2, c-Myc and Klf4. After about 30 days, embryonic stem like colonies started to 
appear. Colonies displaying the characteristic morphology of human ESCs (Figure 1A) could be picked and 
expanded.  
 
 
Figure 1: Characterization of human PBMC derived iPSCs. A) Morphology of hiPSC colony in culture. B) Alkaline phosphate staining 
of cultured hiPSCs C) Quantitative RT-PCR assay for expression analyses of pluripotency markers Oct4, Sox2, Nanog, Rex1, and Dppa3 
in hiPSCs. Data are normalized with GAPDH and relative to PBMC. D-E) Immunostaining for pluripotency markers Oct4, Sox2, Tra-1-
60 and Tra-1-81 in one representative iPSC line. (Dapi in blue) F) In vitro embryoid body (EB)-mediated differentiation of hiPSCs into 
three germ layers. Differentiated cells were analyzed by quantitative RT-PCR for the expression of endodermal (Foxa2 and CXCR4), 
ectodermal (Pax6 and DCX) and mesodermal (MSX1 and Pax3) lineage markers. Data are normalized with GAPDH and relative to 
undifferentiated iPSCs. G-I) H&E staining of teratomas arising of immunodeficient NSG mice. Teratoma containing neural tissues 
(ectoderm) (G), intestinal epithelium (endoderm) (H) and cartilage (mesoderm) (I). (Scale bars: 200µm) All experiments were 
performed for four different clones - Data show results of one representative clone (clone3). 
 
These colonies showed high AP activity (Figure 1B) and highly expressed the pluripotency associated 
transcription factors Oct4, Sox2, Nanog, Rex1, and Dppa3 (Figure 1C). All markers were upregulated 
compared to the original, non-reprogrammed PBMCs, confirming their transition to an undifferentiated 
state. Furthermore, the human specific pluripotency markers Tra-1-81 and Tra-1-60 (Figure 1D and 1E) were 
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also exclusively expressed in the hiPSC colonies. To assess the pluripotent potential of the generated hiPSC, 
cells were first differentiated in vitro into EBs. Analysis of the expression of early differentiation markers 
revealed differentiation into all three germ layers: endoderm (Foxa2 and CXCR4), ectoderm (Pax6 and DCX) 
and mesoderm (MSX1 and Pax3) (Figure 1F). In addition, hiPSCs were injected subcutaneously into NOD-SCID 
mice and teratomas were generated after 10-12 weeks. Histological analyses revealed that cell types 
characteristic for all three germ layers including ectoderm (neural epithelium), mesoderm (cartilage) and 
endoderm (intestinal epithelium) were present (Figure 1G-I). Taken together, these results confirm the 
pluripotent nature of the generated hiPSCs. 
 
3.3.2 Characterization of human iPSC-derived smooth muscle and endothelial cells 
We next investigated the ability of three generated hiPSCs clones to differentiate into SMCs and ECs, in order 
to use them later for vascular TE applications. Under muscle inducing culture conditions, hiPSCs gradually 
lost the expression of the pluripotency genes (Figure 2B) and gained the expression of the SMCs specific 
genes like αSMA, calponin and SMMHC (Figure 2A). Moreover, the hiPSC-derived SMCs showed similar 
marker profile when compared to primary human aortic SMCs for specific SMC markers at RNA and protein 
level (Figure 2A and 2C). Similarly, hiPSC were also able to differentiate into ECs when cultured under specific 
conditions. Three different clones differentiated into ECs showed high expression of the ECs markers CD31, 
von Willebrand factor (vWF) and endoglin (Figure 3A) and concomitantly downregulation of the pluripotency 
markers Oct4, Nanog, and Rex1 (Figure 3B). Moreover, hiPSC-derived ECs expressed markers including CD31, 
vWF and endothelial nitric oxide synthase (eNOS) comparable to human umbilical cord derived endothelial 
cells (Figure 3C). In conclusion, the obtained hiPSC-derived SMCs and ECs were proved to be pure populations 
of differentiated cells, which highly resembled native SMCs and ECs (Figure 2A and 3A). 
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Figure 2: Characterization of differentiated smooth muscle cells (SMCs) from human iPSCs. Human iPSCs were differentiated into 
SMCs A) Quantitative RT-PCR assay for expression analyses of SMC markers αSMA, smoothelin, and calponin. Direct comparison 
between hiPSCs, hiPSC derived SMCs and primary SMCs. B) Quantitative RT-PCR assay for the expression of Oct4, Nanog, and Rex1 
in hiPSC derived SMCs and hiPSC. Data were normalized with GAPDH and relative to the undifferentiated hiPSCs. C) Direct comparison 
of immunostaining for undifferentiated hiPSCs, hiPSC derived SMC, and primary SMCs. Following markers were tested: Oct4, α 
smooth muscle actin (αSMA), calponin, smooth muscle myosin heavy chain (SMMHC), CD31, von Willebrand factor (vWF), and 
endothelial nitric oxide synthase (eNOS). Dapi in blue and respective antibody in red. (Scale bars: 100µm) All experiments were 
performed with three different clones. 
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Figure 3: Characterization of differentiated endothelial cells (ECs) from human iPSCs. Human iPSCs were differentiated into ECs. A) 
Quantitative RT-PCR assay for expression analyses of EC markers von Willebrand factor (vWF), endoglin and CD31. Direct comparison 
between hiPSCs, hiPSC derived ECs and primary ECs. B) Quantitative RT-PCR assay for the expression of Oct4, Nanog, and Rex1 in 
hiPSC derived ECs and hiPSC. Data were normalized with GAPDH and relative to the undifferentiated hiPSCs. C) Direct comparison of 
immunostaining for undifferentiated hiPSCs, hiPSC derived EC, and primary ECs. Following markers were tested: Oct4, α smooth 
muscle actin (αSMA), calponin, smooth muscle myosin heavy chain (SMMHC), CD31, vWF, and endothelial nitric oxide synthase 
(eNOS). Dapi in blue, Phalloidin in red and respective antibody in green (Scale bars: 100µm) All experiments were performed with 
three different clones. 
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3.3.3 Qualitative and quantitative tissue analysis of TEVGs based on human iPSCs 
Human iPSC-derived SMCs and ECs were seeded onto a PGA/P4HB scaffold and cultured under static or 
dynamic conditions. After 3 weeks (Figure 4A-B) the constructs were retrieved for histological analysis. H&E 
staining (Figure 4C-F) demonstrated formation of significant amounts of extracellular matrix (ECM) in vitro. 
 
Figure 4: Qualitative and quantitative tissue analysis of TEVGs based on human iPSCs. Human iPSC-derived proliferative SMCs were 
seeded onto a PGA/P4HB scaffold and the scaffold construct were cultured under static or dynamic conditions. A-B) Macroscopic 
photos of TEVGs after 3 weeks of culture. C-F) H&E staining show tissue formation under both conditions. G-J) Masson’s trichrome 
display collagenous extra cellular matrix formation after static and dynamic culture. K-L) Polarization microscopy revealed the 
presence of the initial scaffold matrix. M) Extracellular matrix analysis shows the amount of hydroxyproline (HYP), 
glycosaminoglycans (GAG), and the cell number (deoxyribonucleic acid, DNA) of TEVGs (n=4), which were statically or dynamically 
cultured (all values relative to control samples (ctrl) indicating biomaterials only). (Scale bars: 500µm) 
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TEVGs under static conditions (Figure 4C-D) displayed high cellularity and layered tissue on the outer vessel 
regions, while in the central part of the scaffold low cellularity and no visible formation of ECM were present. 
In contrast, TEVGs under dynamic conditions (Figure 4E-F) exhibited high cellularity and tissue formation on 
the outer as well as on the inner vessel regions. Nonetheless, low cellularity was demonstrated between 
these two layers compared to native controls. In order to visualize the deposition of collagen fibers Masson 
Trichrome staining was used (Figure 4G-J). Dynamically cultured TEVGs (Figure 4I-J) represented a better 
collagenous ECM deposition on the outer as well as on the inner vessel regions in comparison to TEVGs under 
static conditions (Figure 4G-H). In general, vascular grafts cultured under dynamic conditions showed a better 
cellular infiltration and tissue formation in comparison to static culture. Polarization microcopy revealed the 
presence of initial scaffold matrix in the central part of the constructs (Figure 4K-L). However, in dynamic 
constructs the biomaterial remnants were more degraded (Figure 4L) compared to static constructs (Figure 
4K). The co-polymer starter matrices showed no major remodeling in the central part of the constructs under 
static as well as dynamic conditions given the lack of tissue formation in this area of the constructs. PGA 
fibers were visible as elongated ellipses. In order to quantify the composition of ECM, TEVGs were 
biochemically analyzed by using assays for HYP, GAG, and the cell number (DNA) (Figure 4M). Generally, all 
three hiPS cell lines (color pattern) displayed similar amounts of HYP, GAG and DNA for respective conditions 
with no significant differences detectable indicating lack of interindividual differences. Overall dynamic 
conditions (n=4) showed a significantly higher expression of DNA (p<0.05), GAG (p<0.05), and HYP (p<0.05) 
in comparison to static conditions (n=4). These findings underline the histological observations. 
 
3.3.4 Immunofluorescence of TEVGs  
To determine the cellular phenotypes in the TEVGs derived from hiPSCs, cells were stained for αSMA and 
vWF. Immunofluorescence stainings of TEVGs under static as well as dynamic conditions demonstrated 
layered tissue architecture with an αSMA positive layer located in the interstitium and a thin luminal layer of 
vWF positive cells comparable to native vessels (Figure 5). In general, the αSMA positive layer of TEVGs are 
thinner in comparison to native tissue. The majority of cells stained positive for αSMA were located at the 
outer layer of the statically cultured TEVG. In contrast to the static culture, dynamically cultured TEVG show 
a thicker αSMA positive layer. 
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Figure 5: Comparative immunohistochemical anaylsis of tissue engineered vascular grafts (TEVGs) based on human iPSCs 
versus native arteriole. Immunohistological analyses of TEVGs under static and dynamic conditions (n=3) revealed positive 
expression of the smooth muscle cell marker alpha smooth muscle actin (αSMA) in the interstitium (green) and a thin luminal 
positive layer of endothelial cell marker von Willebrand factor (vWF) (red) (Dapi in blue). (Scale bars: 100µm) 
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3.4 Discussion 
 
In vitro engineering of small diameter native-like vascular grafts is still demanding as poor 
haemocompatibility of TEVGs often leads to thrombosis and stenosis when implanted in vivo [5]. Therefore, 
creating a functional biomaterial that closely mimics the native layered architecture of blood vessels would 
represent a major step towards the functional replacement of disease vascular structures.  
The current study is the first report showing the possibility to employ human PBMC-derived iPSCs to generate 
synthetic scaffold-based TEVGs, which contained a αSMA-positive layer in the graft interstitium as well as a 
thin luminal layer of vWF-positive cells comparable to native vessels. Importantly, given the ease of access, 
this PBMC-based approach may open up the possibility to generate native-like endothelialized ‘customized’ 
TEVGs i) to study complex human diseases in vitro not only enabling better understanding of the 
pathophysiology, but ii) ultimately also allowing for assessment of novel therapeutic approaches in the 
future. 
Our data highlights the possibility to reprogram PBMCs to hiPSCs and make use of these cells for engineering 
small diameter vascular graft. The use of PBMCs has clear advantages compared to skin fibroblasts. 
Previously, the most common source to generate hiPSCs has been skin fibroblasts [18, 20]. Exposure of the 
dermis to ultraviolet (UV) light increases the risk for chromosomal aberrations [21], further, fibroblast cells 
need to expand for several passages in vitro and make it a cumbersome cell source for reprogramming. In 
addition, taking skin biopsies usually results in scar tissue formation and might not be feasible for non-
therapeutic disease modeling settings or in volunteers. Beyond that, skin represents a non-reconstituting 
organ not providing unlimited supply to a certain donor tissue, implying that repetitive cell harvest seems 
difficult. In contrast, peripheral blood is a constantly reconstituting source of patient tissue that is not 
exposed to UV radiation. However, it represents a low invasive and well established cell source – a cell source 
one could use for large scale, repetitive isolation of sterile, viable, autologous, cellular material from patients 
as well as voluntary donors. 
Our small diameter vascular graft displaying a layered tissue architecture similar to the native structure 
present in human vessels based on reprogramming PBMCs into hiPSC. These human PBMC-derived iPSCs 
were hence successfully differentiated into SMCs and ECs for their use in TE. The differentiated SMCs and 
ECs were seeded onto biodegradable polymer scaffolds and cultured under static or dynamic conditions in a 
bioreactor for inducing vascular tissue formation in vitro.  
Various reprogramming techniques have been established during last years for generating hiPSCs [22]. 
Currently, four main categories can be subdivided into: integration-defective viral delivery, episomal delivery, 
RNA delivery and protein delivery [22]. The original method of reprogramming murine fibroblasts by 
Yamanaka utilized retroviral transduction of Oct4, Sox2, Klf4, and c-Myc into MEF [18]. As lentiviruses, unlike 
retroviruses, can infect non-dividing and proliferating cells, this approach became the most preferred 
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reprogramming approach. In particular, for clinical applications reducing genomic modifications to prevent 
insertional mutagenesis seems important, that is why more and more non-integrative or semi-integrative 
approaches have been developed. For example, our group recently established reprogramming of human 
cells into iPSC using a transgene-free approach [23]. The present study successfully achieved hiPSC 
reprogramming by simultaneously expressing the Yamanaka factors lentiviral vectors. Notwithstanding, in 
order to obtain cells suitable for clinical application, transgene-free hiPSCs need to be generated to avoid 
transgene reactivation, altered gene expression and misguided differentiation. Thus, future studies will 
establish PBMC-derived patient-specific, integration-free hiPSC and differentiate them into SMCs and ECs for 
TE applications. 
In this study, hiPSC-derived TEVGs were generated under static and dynamic culture conditions. In general, 
vascular grafts cultured under dynamic conditions showed histologically an increased cellularity, tissue 
formation and scaffold degradation in comparison to static culture. In addition, dynamically cultured TEVGs 
expressed a significantly higher amount of DNA, GAG and HYP than static cultured TEVGs. It has been shown 
that mechanobiological interactions between cells and scaffolds can crucially influence cell behavior [24]. 
Wang et al. also showed an enhanced cell proliferation under dynamic three-dimensional (3D) culture 
compared with conventional static two-dimensional (2D) and 3D cell culture conditions [25]. In the field of 
vascular tissue engineering, a study using cyclic mechanical loading was reported by Niklason and colleagues 
[26]. In this study, tubular meshes of PGA were seeded with adult bovine aortic smooth muscle cells and 
placed around distensible silicone tubes for 8 weeks [26]. Finally, TE arteries were implanted in miniature 
swine, with patency up to 24 days.  
The long-term patency of small-diameter vascular grafts is still a great challenge in the field of cardiovascular 
TE research. Early luminal thrombosis represents the major cause of vessel occlusion. A possible solution 
should be the coating of the grafts with antithrombogenic materials, such as heparin [27] or ethylene oxide 
[28], but the results were not satisfactory. The vascular TE approach has been introduced to generate 
vascular grafts with functional endothelium potentially enabling long-term patency [29]. This project showed 
the production of hiPSC-derived TEVGs, which contained an αSMA-positive layer in the interstitium and a 
thin luminal layer of vWF-positive cells comparable to native vessels. Gui et al. also observed thrombus 
formation in some samples, possibly due to the lack of endothelial cell coating of vascular grafts before 
implantation [30]. This underlines the impact of a functional endothelial cell layer in TEVGs. Future efforts 
will focus on the implantation of our TEVGs also to investigate the in vivo functionality and patency of human 
PBMC-iPSC-based TEVGs compared to mature vascular cell-derived constructs. 
In the past, murine [31] and hiPSCs [32] were differentiated into SMCs and used to construct a TEVG for 
subcutaneous implantation for 2 weeks. Furthermore, Gui et al. implanted a hiPSC-derived TEVG into nude 
rats as abdominal aorta interposition for 2 weeks [30]. These TEVG contained α-SMA and SMMHC-positive 
cells [30]. So far, these studies are based on the reprogramming of human fibroblasts. Recently, Hu et al. 
established integration-free reprogrammed hiPSC from PBMCs and then differentiated the cells into 
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mesoderm-originated cardiovascular progenitor cells (CVPCs) [33]. Subcutaneous implantation of CVPCs 
seeded on a disc shaped scaffold led to in vivo lineage specification [33]. Nevertheless, there is no TEVGs 
based on SMCs and endothelial cells (ECs) differentiated from PBMC-derived hiPSC available yet. 
Taken together our data show for the first time that it is possible to employ pre-differentiated human ECs 
and SMCs generated with PBMC-derived hiPSCs to produce vascular grafts comparable to native vessels.  
 
Conclusion 
Human iPSCs generated from PBMCs is a promising cell source for TE as they are easily accessible and may 
thus serve as a versatile platform also involving disease modeling applications. In addition to solving ethical 
concerns related to the use of blastocyst-derived ESC, the use of hiPSCs for the generation of therapeutic 
cells may avoid the requirement for post-transplant immunosuppression. Upon appropriate differentiation, 
these cells can then be used to study normal and pathologic human tissue development in vitro, enabling 
new insights into disease pathology as well as the development of novel therapeutic agents and patient-
specific cellularized replacements. In summary, our study established an efficient approach towards 
generating patient-specific TEVGs based on human PBMC-iPSC-derived SMCs and ECs, containing a native-
like layered vessel architecture. 
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3.5 Supplementary Data 
 
Gene Forward Primer Reverse Primer 
GAPDH ACCACAGTCCATGCCATCAC TCCACCCTGTTGCTGTA 
Dppa3 GCTCACCGAAGAAAATTCCCG GTTTGTTGGTCTTCTTTCATGCGTA 
Nanog ATACCTCAGCCTCCAGCAGA GAGGCCTTCTGCGTCACAC 
Oct4 GAGAAGCTGGAGCAAAACCC ACCTTCCCAAATAGAACCCCC 
Sox2 AACCAGCGCATGGACAGTTA GACTTGACCACCGAACCCAT 
Rex1 CATCGCTGAGCTGAAACAAATG CTGCAGGTCTTGGCTTGACT 
FOXA2 GGAGCAGCTACTATGCAGAGC CGTGTTCATGCCGTTCATCC 
CXCR4 ACTACACCGAGGAAATGGGCT CCCACAATGCCAGTTAAGAAGA 
Pax6 TGGGCAGGTATTACGAGACTG ACTCCCGCTTATACTGGGCTA 
DCX TCCCGGATGAATGGGTTGC GCGTACACAATCCCCTTGAAGTA 
MSX1 ACACAAGACGAACCGTAAGCC CACATGGGCCGTGTAGAGTC 
Pax3 AGCTCGGCGGTGTTTTTATCA CTGCACAGGATCTTGGAGACG 
Calponin CCTCTGCTCACTTCAACCGA TTCTGGGCCAGCTTGTTCTTA 
Smoothelin CCTACCCTGGGTTTGAATTCTC GAGTGCAGCCAGTTCTCCTT 
αSMA GTGTTGCCCCTGAAGAGCAT GCTGGGACATTGAAAGTC 
CD31 GAAATGTCCAGGCCAGCAGT ATCTGCTTTCCACGGCATCA 
vWF GACGCCATCAACACCGAGTT CTTTGTCGTTGGTTAGCTGGT 
Endoglin TGCACTTGGGATACAATTCCA AGCTGCCCACTCAAGGATCT 
Supplemental Table 1: Primers list
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Primary antibody Company Dilution 
anti-OCT4 (C52G3)  Cell Signaling, USA 1:200 
anti-SOX2 (D6D9) Cell Signaling, USA 1:200 
anti-Tra-1-60 Biotin  eBioscience, Austria 1:200 
anti-Tra-1-81 Biotin  eBioscience, Austria 1:200 
Anti αSMA (1A4) Abcam, United Kingdom 1:200 
Anti calponin (HCP) Sigma-Aldrich, Switzerland 1:200 
Anti SMMHC (AB53219) Abcam, United Kingdom 1:200 
Anti CD31 (JC70A) Dako, USA 1:200 
Anti eNOS Abcam, United Kingdom 1:200 
Anti vWF eBioscience, Austria 1:200 
Phalloidin Life Technologie, Switzerland 1:50 
Dapi Sigma-Aldrich, Switzerland 1:2000 
Secondary antibody Company Dilution 
anti rabbit Alexa Fluor 594 Invitrogen, USA 1:1000 
anti mouse Alexa Fluor 594  Invitrogen, USA 1:1000 
anti mouse Alexa Fluor 488  Invitrogen, USA 1:1000 
anti rabbit Alexa Fluor 488 Invitrogen, USA 1:1000 
Supplemental Table 2: Antibodies list 
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4.1 The optimal material for TE applications: Synthetic vs. natural 
For tissue engineering applications, the expanded cells are seeded onto a biodegradable scaffold. The 
biomaterial mimics the biologic and mechanical function of the native ECM found in tissues in the body 
by serving as an artificial ECM. Generally, three classes of biomaterials have been investigated for 
engineering tissues: (i) naturally-derived materials, (ii) acellular tissue matrices, and (iii) synthetic 
polymers.  
The present study aimed at a systematic, multimodal comparison of three frequently used synthetic 
polymers for the in vitro engineering of extracellular matrix based on PGA which is the most common 
used polymer for TE applications under static as well as dynamic conditions.  
Due to their high durability and mechanical strength several synthetic polymers have been used in the 
attempt to produce scaffolds for TE applications, including PGA, P4HB, PLA, and PCL: Therefore, three 
human fibroblast cell lines were seeded on either PGA-P4HB, PGA-PLA or PGA-PCL patches. These 
patches were analyzed after 21 days of culture qualitatively by histology and quantitatively by 
determining the amount of DNA, GAG and HYP. We found that PGA-P4HB and PGA-PLA scaffolds 
stimulate tissue formation significantly higher than PGA-PCL scaffolds (p<0.05). Polymer remnants 
were visualized by polarization microscopy. The degradation products of PGA, PLA, and P4HB are non-
toxic, natural metabolites and are eventually eliminated from the human body [1, 2]. The degradation 
rate of these polymers can be adjusted from several weeks to several years by altering crystallinity, 
initial molecular weight, and the copolymer ratio of lactic to glycolic acid [2]. In addition, biomechanical 
properties of the tissue engineered patches were determined in comparison to native tissue. PGA-PLA 
and PGA-P4HB TE patches show similar biomechanical properties. Both hybrid polymers are more 
ductile and flexible in comparison to PGA-PCL. Production conditions of synthetic polymers can be 
tightly regulated, thus, mechanical and physical properties are predictable and well-defined [3]. Taken 
as a whole, all PGA based scaffolds showed tissue formation after 3 weeks of culture and mechanical 
flexibility and strength.  
In addition, synthetic polymer scaffolds are less expensive, better reproducible and may be stored off-
the-shelf over longer time periods [4]. These characteristics make them an interesting raw material for 
scaffold fabrication. Nevertheless, their biocompatibility issues harbor also complications.  
Natural polymers usually contain specific molecular domains that can promote and guide cells and can 
thus enhance biological interaction of the scaffold with the host tissue [5]. Natural scaffolds composed 
of ECM proteins are a promising alternative for tissue repair and regeneration. These types of scaffolds 
have been shown to support the interaction with the surrounding host tissue, to induce the deposition 
of cells and ECM, and to accelerate the process of angiogenesis [6]. However, producing scaffolds from 
natural materials with homogenous and reproducible structures is quiet challenging. Additionally, 
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these scaffolds show poor mechanical properties, which leads to a limited use [3]. In contrast, we 
showed that PGA-PCL represents a robust scaffold material. 
Table1 summarizes the advantages and disadvantages of synthetic and natural scaffolds for TE. In 
order to enhance the biological capacity and to overcome the disadvantages of these individual 
biomaterials, groups have combined synthetic with natural polymers [7, 8]. Future studies will focus 
on an adaptation of the concentrations of the used synthetic polymers, also in combination with 
natural polymers for TE applications.  
 
 
Natural Polymers Synthetic Polymers 
ADVANTAGES Biocompatible 
Non-toxic degradation 
Abundant in the natural environment 
Easy processable 
Controlled synthesis 
Physical properties flexible 
Good mechanical properties 
DISADVANTAGES Weak mechanical properties 
Hard processable 
Undefined degradation rate 
Possible toxic degradation products 
High production costs 
Low biocompatibility 
Table1: Natural versus synthetic polymers 
4.2 Technical advances in iPSC generation 
In 2006, Yamanaka and Takahashi evaluated 24 genes thought to be relevant for pluripotency and 
introduced them into mouse fibroblast cells using retroviral transduction system [9]. Finally, they 
proved that only four genes are required to generate ESC-like cells. In order to translate the iPSC 
technology into clinical applications, suitable techniques of factor delivery and efficient identification 
and isolation of reprogrammed cells are essential. Therefore, significant efforts have been investigated 
in the field of iPSC generation and identification by several groups around the globe. Already one year 
after the first generation of iPSCs, Thomson et al. successfully reprogrammed human fibroblasts using 
a lentiviral system [10]. As lentiviruses, unlike retroviruses, can infect non-dividing and proliferating 
cells, this approach became the most preferred reprogramming approach. The present study 
successfully achieved hiPSC reprogramming by using lentiviral delivery. However, the use of integrating 
viruses as a delivery system could lead to undesired insertional mutagenesis in the target cells. In order 
to obtain cells suitable for clinical application, many approaches to generate transgene-free hiPSCs 
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have been employed, such as plasmids [11], Sendai virus [12], adenovirus [13], protein compounds 
[14], small molecules [15], and microRNAs [16]. 
Standardized protocols for general cell products are required for clinical use of iPSCs. The first culture 
condition for human pluripotent stem cells was established for maintaining human ESCs [17]. This 
medium contained several animal-derived products including mouse embryonic fibroblasts for feeder 
layers and fetal bovine serum (FBS) in culture medium. This culture system was successfully adapted 
to human iPSCs, and it maintained their pluripotency and self-renewal [18]. During the last years, 
removal of animal-derived feeder cells and chemically defined conditions for culturing hiPSCs have 
attracted growing attention. As an alternative for culturing hiPSCs without a feeder layer, Matrigel has 
been proven to be a useful option that allows stable culture of human pluripotent stem cells [19, 20]. 
Nevertheless, matrigel is derived from Engelbreth-Holm-Swarm mouse tumor, and thus his condition 
was not animal product-free [21]. Other xeno-free agents, for example recombinant proteins [22, 23] 
and synthetic polymers [24, 25] have been studied and used as feeder-free substitute for generation 
and culture of human pluripotent cells. Furthermore, to remove FBS that might cause the 
differentiation of human ESCs, knockout serum replacement (KSR) has now been established for 
maintaining human ESCs [26] and hiPSCs [18]. In addition, mTeSR1 medium was developed as a 
chemically defined medium for maintaining human pluripotent cells [27]. However, both KSR and 
mTeSR1 also contain animal-derived products and new media have now been developed as xeno-free 
media for maintaining human pluripotent stem cells, such as TeSR2 [28] and Essential E8 [22]. In our 
study, we have generated and maintained hiPSCs on a mouse feeder layer with ESC media containing 
KSR. Developing animal product-free conditions for iPSC generation is also an important practice for 
achieving safe therapies, thus, future studies will establish PBMC-derived patient-specific, integration-
free hiPSC under xenogene-free conditions. 
4.3 Equivalency of iPSCs and ESCs: Are iPSCs different from ESCs?  
After the establishment of the first iPSCs, researchers were impressed by the remarkable similarity to 
ESCs for years [9]. ESCs and iPSCs share two key characteristics in common: (i) ability to self-renew and 
(ii) they can differentiate into cells from all three germ layers. During the last years, however, scientists 
started reporting more and more differences between iPSCs and ESCs [29, 30]. Analyses of genome-
wide expression patterns and global histone modifications have demonstrated a high degree of 
similarity between ESCs and iPSCs [31-33]. Deng et al. first discovered differences in DNA methylation 
between both pluripotent stem cell types [34]. Later other groups reported differentially methylation 
as well, including BMP3 [35]. However, other studies showed that it is difficult to distinguish iPSCs from 
ESCs by gene expression or DNA methylation [36]. Interestingly, by a detailed examination how many 
clones were evaluated, a clear tendency was detected by Yamanka [37]. Studies with a relatively small 
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number of clones reported differences, whereas reports with many more clones found it difficult to 
distinguish between ESCs and iPSCs based on gene expression or DNA methylation [37]. 
Essential differences between these two pluripotent cell types have been reported for the 
differentiation ability. For instance, a reduced neuronal differentiation potential has been shown for 
12 hiPSC lines [38]. ESC clones showed a differentiation efficiency of 90%, in contrast iPSC clones only 
differentiated with 10 to 50% efficiency [38]. Additionally, iPSCs derived from human and murine 
fibroblasts can differentiate into functional cardiomyocytes [39, 40]. However, iPSCs displayed a 
delayed and less efficient differentiation of beating cardiomyocytes compared with ESCs [41]. In 
addition, variation exists regarding the expression of genetic markers in iPSC-derived cardiac cells as 
compared to ESC-derived cardiomyocytes [41, 42]. We have generated hiPSCs from PBMCs and 
differentiated them into αSMA- and calponin-positive SMCs as well as ECs positive for CD31, vWF and 
eNOS that highly resembled native SMCs and ECs. The hiPSC-derived SMCs and ECs showed similar 
marker profile when compared to primary human aortic SMCs, respectively primary human ECs for 
specific markers at RNA and protein level. Although multiple differentiation protocols have been 
established, there is still a substantial variability in the efficiency of generating differentiated lineages 
among independent iPSCs andESCs [43]. 
4.4 Therapeutic potential of iPSC 
Human iPSCs are a promising cell source in the field of regenerative medicine as they are easily 
accessible and may thus serve as a versatile platform also involving disease modeling applications. In 
addition to solving ethical concerns related to the use of blastocyst-derived ESCs. The use of hiPSCs 
allows for cell transplantation without the need for any immunosuppression or possible allogeneic 
tissue immune rejection given their autologous nature. Upon appropriate differentiation, these cells 
can then be used to study normal and pathologic human tissue development in vitro, enabling new 
insights into disease pathology as well as the development of novel therapeutic agents and patient-
specific cellularized replacements. Figure 1 presents potential applications of hiPSCs. 
 
4.4.1 Cell therapy 
Since their discovery, iPSCs have captured the imagination of researchers and clinicians seeking to 
develop patient-specific therapies. Currently, several clinical trials evaluating stem cell therapy 
products are ongoing [44, 45]. Nevertheless, until today there has been only one clinical trial involving 
iPSC-derived cells to treat wet-type macular degeneration (AMD) [46]. Wet-eye AMD is associated with 
an abnormal growth of new blood vessels behind the retina, which causes the progressive damage of 
the retinal pigment epithelial (RPE) cells. Therefore, RPE sheets derived from the patient`s own iPSCs 
were transplanted into the right eve of a 70-year old female patient [46]. 
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Figure 1. Applications for iPSCs.  
iPSCs enable to develop new models to study human disease and represent a significant step towards patient-specific cell replacement 
therapies. 
 
The therapy resulted in a stabilization of her visual acuity and stopping macular degeneration. 
However, the trial was stopped owing to two mutations detected in the RPE cells that were not present 
in the patient`s original fibroblast cells [47, 48]. These findings underline that there are still hurdles 
related to iPSC-based therapies that will need to be addressed before routine clinical applications can 
start. One issue is the risk of tumorigenicity from iPSCs, as well as, from ESCs [49]. During long culture 
periods pluripotent cell can accumulate karyotypic abnormalities and copy number variants [50]. Thus, 
it is even more important to carefully screen iPSC-derived products for risky genetically aberrations 
before clinical use. Interestingly, products differentiated from iPSCs have not been shown to generate 
teratomas [51, 52]. Thus, standardized protocols for differentiating hiPSCs with specific identity and 
cellular function are essential, as well as, the elimination of undifferentiated cells. 
Another promising study suggest that the treatment of genetic disorders with iPSCs could be feasible. 
Already in 2007, Hanna et al. demonstrated the use of iPSC to rescue the defects seen in an animal 
model of sickle cell anemia [53]. Sickle cell anemia relies on a single point mutation in the hemoglobin 
gene. In this study, murine skin cells were reprogrammed into iPSCs and subsequently the disease-
causing mutation was corrected by gene targeting [53]. The healthy progenitors were transplanted 
into anemic mice. Finally, the transplanted cells produced normal red blood cells and cured the disease 
[53]. In theory, this approach could be adapted to any disease in humans with a known mutation and 
that can be treated by cell transplantation. 
In addition, autologous iPSCs might reduce the high costs and side effects related to the requirement 
of lifelong immunosuppression for allogeneic cell transplantation [54]. Furthermore, recent studies 
have shown that the differentiation of iPSC could lead to loss of immunogenicity [55, 56]. 
 
  General Discussion 
 107 
 
4.4.2 Disease modeling and Drug discovery 
The study and treatment of many diseases, such as type I diabetes, Alzheimer`s disease, and 
Parkinson`s disease is limited by the availability of the affected tissue, as well as insufficient culture 
conditions to grow the cells. Therefore, iPSCs provide an unlimited source of proliferating cells and 
overcome the constraints of confined donor cell availability as well as limited proliferation capacity. 
The potential of using iPSCs for disease modelling in vitro and to generate new diagnostic / therapeutic 
approaches provide excellent platforms for studying human diseases in a dish. A growing number of 
researchers have employed iPSCs for modelling a variety of diseases, including diseases of the 
hematopoietic [57-59], neurological [60-62], endothelial [63], and cardiovascular [64, 65] system. They 
demonstrated the possibility of using patient-derived iPSCs for reproduction of human disease 
phenotypes and their potential application in the use of these cells for drug screening. Our study 
showed the generation of hiPSCs based on PBMCs and differentiation into αSMA- and calponin-
positive SMCs as well as ECs staining positive for CD31, vWF and eNOS. These cells were seeded onto 
PGA-P4HB starter matrices and cultured under static or dynamic conditions to induce tissue formation 
in vitro. Resulting TEVGs showed abundant amounts of extracellular matrix, containing a αSMA-
positive layer in the interstitium and a thin luminal layer of vWF-positive cells approximating native 
vessels. These results pave the way for developing autologous PBMC-derived hiPSC-based vascular 
constructs for therapeutic applications or disease modeling. 
Another interesting approach is the use of hiPSCs for the production of organoids. Recently, Qian et al. 
generated brain organoids based on hiPSCs to clarify whether and how infection of the Zika virus in 
pregnant woman could lead to microcephaly during development of the fetus [66]. After exposure to 
the virus, it mainly infected neural stem cell progenitors leading to cell death and reduced proliferation 
[66]. These and other findings have helped to understand the mechanism of this disease. 
The ultimate goal is to gain greater insight into mechanisms of human disease or to develop new and 
improved therapies or diagnostics. Although great advances have been made in terms of developing 
disease models in animals, such as transgenic mice, there are several limitations when focusing on the 
translation of the data generated with regards to human disease. There have already been drugs 
developed, which show therapeutic effects in rodent models, but are inefficient in the human 
situation. An example for this represents the field of the amyotrophic lateral sclerosis [67]. In contrast, 
when iPSCs were exposed to experimental drugs for specific diseases, the “symptoms” were partially 
alleviated in culture [33]. Therefore, disease modeling with human iPSCs represents an indispensable 
step for the development of therapies for human disease. 
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